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Abstract
Following a request from the European Commission to EFSA, the EFSA Scientiﬁc Committee (SC)
prepared a guidance for the risk assessment of substances present in food intended for infants below
16 weeks of age. In its approach to develop this guidance, the EFSA SC took into account, among
others, (i) an exposure assessment based on infant formula as the only source of nutrition;
(ii) knowledge of organ development in human infants, including the development of the gut,
metabolic and excretory capacities, the brain and brain barriers, the immune system, the endocrine
and reproductive systems; (iii) the overall toxicological proﬁle of the substance identiﬁed through the
standard toxicological tests, including critical effects; (iv) the relevance for the human infant of the
neonatal experimental animal models used. The EFSA SC notes that during the period from birth up to
16 weeks, infants are expected to be exclusively fed on breast milk and/or infant formula. The EFSA
SC views this period as the time where health-based guidance values for the general population do not
apply without further considerations. High infant formula consumption per body weight is derived from
95th percentile consumption. The ﬁrst weeks of life is the time of the highest relative consumption on
a body weight basis. Therefore, when performing an exposure assessment, the EFSA SC proposes to
use the high consumption value of 260 mL/kg bw per day. A decision tree approach is proposed that
enables a risk assessment of substances present in food intended for infants below 16 weeks of age.
The additional information needed when testing substances present in food for infants below 16 weeks
of age and the approach to be taken for the risk assessment are on a case-by-case basis, depending
on whether the substance is added intentionally to food and is systemically available.
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Summary
Upon a request by the European Commission to the European Food Safety Authority (EFSA), a
guidance was prepared by the EFSA Scientiﬁc Committee (SC) for the risk assessment of substances in
food intended for infants below 16 weeks of age, taking into particular consideration the procedures to
derive health-based guidance values (HBGV).
The EFSA SC considered that for the purpose of this guidance, the term ‘infants below the age of
16 weeks’ was used to describe the particular infant subpopulations where HBGV had traditionally not
been considered applicable. This population includes preterm neonates receiving enteral feeding.
In preparing this guidance, the EFSA SC considered the physiological, developmental and nutritional
aspects that are speciﬁc for infants below 16 weeks of age, with particular attention to the latest
scientiﬁc developments in the ﬁeld.
The EFSA SC concluded that high infant formula consumption per body weight is derived from 95th
percentile consumption with the ﬁrst weeks of life being the time of the highest relative consumption
on a body weight basis. Therefore, when performing an exposure assessment for substances in infant
formula, the EFSA SC proposes to use the highest consumption ﬁgure reported for the period of
14–27 days of life, which corresponds to a value of 260 mL/kg body weight (bw) per day. This value
would also cover the potential high consumption rates of preterm infants on enteral (formula) feeding
and can be used when carrying out an exposure assessment of substances intentionally or not
intentionally added to food, such as contaminants. For the exposure assessment, infant formula is
expected to be the only source of nutrition for the ﬁrst 16 weeks of life in non-breastfed infants.
Gastric, pancreatic and biliary functions are not fully mature at birth. However, preterm and term
neonates display a mature-type intestinal epithelium. The local effects of a substance on the
gastrointestinal tract, its absorption and its systemic fate will depend on local pH, transit time, size of
the absorptive surface or its metabolism by the gastrointestinal wall and by the bacterial microbiome,
all parameters changing during post-natal maturation.
Absorption of substances in general might be slower in infants below 16 weeks of age than in older
ones, although the amount absorbed is not dependent on the age. Once absorbed and systemically
available, the distribution of the substance may be different from that in adults owing to the age-
dependent changing of body composition (neonates: larger extracellular and total-body water spaces
and lower fat content). Other factors to be considered are the differences in regional blood ﬂow, organ
perfusion and cardiac output between infants and adults. In addition, total plasma protein binding
capacity (in particular albumin) is lower in infants.
Infants show a unique pattern of development for individual enzyme isoforms involved in phases I
and II metabolism, with a reduced capacity at birth. However, owing to overlapping substrate
speciﬁcities, the overall impact on the clearance and half-life of substances (decrease in clearance,
increase in half-life) is limited, being generally up to two- (full-term) to threefold (preterm) lower when
comparing infants with healthy adults. Likewise, renal function is also reduced at birth and increases in
the ﬁrst year of life. Therefore, if the precise metabolic pathway is not known and if it is not known to
which extent the substance is excreted by metabolic elimination or by renal excretion, an additional
uncertainty factor (UF) of 3 should be considered as a conservative option to account for the reduced
elimination/excretion. When the precise metabolic pathway for a given substance is known, reported
age-speciﬁc ratios child/adult can be used. In rare instances where the data are available for the
metabolic clearance for this age group, then chemical-speciﬁc uncertainty factors can be used. Preterm
infants under medical supervision would not be sufﬁciently protected by the additional UF of 3 due to
the considerable immaturity of the absorption, distribution, metabolism and excretion (ADME) system,
and would necessitate a case-by-case approach. For compounds, for which effects are depending on
long-term body burden (e.g. cadmium, dioxins), the impact of immaturity of metabolism and excretion
is likely to be minimal.
The developing blood–brain barrier (BBB) is similar to the adult BBB, in that it possesses functional
tight junctions and inﬂux and efﬂux transporters. Hence, contrary to previous assumptions, the healthy
BBB in the ﬁrst 16 weeks, although immature, is considered functional and not leaky. However, the
expression/activity of transporters and metabolising enzymes appears to vary from adult patterns to
meet the needs of the developing brain. The movement of molecules across the BBB depends on their
physicochemical properties, the local physiological milieu (e.g. pH) and the need for transporters and
their ontogeny, activity and speciﬁc location. The differences may result in greater vulnerability to
chemicals than in the adult. Uncertainty in predicting speciﬁc exposure of the central nervous system
(CNS) to chemicals derives from knowledge gaps concerning the degree to which alternative pathway
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barriers such as the blood choroid plexus barrier are functional and the precise differentiation state of
the BBB.
The developing immune system in fetal and early post-natal life is particularly sensitive and
exposure to immunotoxicants may result in persistent effects on the immune system that last or
appear only long after exposure and in general, and may also occur at lower doses than during adult
exposure. In addition, the effects on immune function seen upon perinatal or adult exposure may be
different. A number of compounds or types of exposure may produce different ranges or severities of
outcomes depending on the time of exposure during the immune system development. Different and
unpredictable arrays of alterations (quantitative and qualitative) may be expected when the exposure
occurs in utero or in the early neonate vs adult exposure. They may be associated with chronic
immunological conditions such as autoimmunity, immune deﬁciency, inﬂammation and allergic
reactions. Altogether, neonates have speciﬁc features in the development and maturation of their
immune system, which make their response to an immunogenic/allergenic compound different from
that of an adult and therefore deserve speciﬁc studies.
The development of the female reproductive system in infants below 16 weeks of age is relatively
quiescent. However, for the development of the male reproductive organ, the testis, this is a sensitive
period. The early post-natal testis exhibits a high proportion of immature Sertoli cells, which proliferate
from birth until 6 months of age when the adult number of Sertoli cells is achieved. Effects on the
development of the reproductive organs generally may become apparent later in life.
Infants below 16 weeks of age have speciﬁc endocrine proﬁles that are different from those in
adults. This suggests that such differences may require particular attention for risk assessment of
chemicals, such as those targeting the thyroid. Effects at any early developmental stage may be
reﬂected in deﬁcits at later time points, indicating that the window of exposure, the window of
maximum sensitivity and the window of effect require a lifespan approach to generate a fully
protective risk assessment.
The EFSA SC notes that, during the period from birth up to 16 weeks, infants are expected to be
exclusively fed on breast milk and/or infant formula. The EFSA SC views this period as the time where
HBGV for the general population do not apply without further considerations. The EFSA SC made the
following considerations when developing a testing strategy for substances in food for infants below
16 weeks of age. Testing strategies for substances present in food for infants need to take into
consideration the differences in development stages of the relevant organ systems and the related
critical windows of maximum sensitivity between humans and laboratory animals used in safety
testing. The safety evaluation of substances that may be present (intentionally or not) in the foods
consumed by infants below the age of 16 weeks of age should follow the general principles set for the
safety evaluation processes used for older infants and adults and can make use of information already
obtained in such studies. The testing programmes for the safety evaluation of substances in food used
for the general population will depend on the applicable guidance and legislations. Typically, these
studies will provide information on ADME, subchronic and chronic toxicity, genotoxicity, carcinogenicity
and reproductive toxicity. However, in view of the potential greater sensitivity during the ﬁrst few
weeks of life, the EFSA SC considers that additional studies may be necessary for the risk assessment
of substances present in food consumed by this population.
The EFSA SC has endorsed the following approach to evaluate the safety of substances in food for
infants below 16 weeks of age and has developed the following decision tree approach to support a
risk assessment.
For substances added intentionally to food for infants below 16 weeks of age, an Extended One-
Generation Reproductive Toxicity Study (EOGRTS) (OECD TG 443) would be required. The EOGRTS
should include cohorts to assess the potential impact of a test substance on the reproductive and
developmental system, on the developing nervous system and on the developing immune system.
Because exposure through mother’s milk in experimental studies is usually substantially lower than the
exposure through feed, the resulting doses in the neonatal animals may be insufﬁcient for hazard
characterisation. Therefore, for the purpose of this guidance, it is advised that direct dosing of the
neonatal animals should be considered as soon as possible after birth. When standard toxicological
studies do not show adverse effects in adult animals and the ADME studies show that a substance is
not absorbed in relevant amounts, only a repeated dose study with direct oral administration to
neonatal animals (e.g. in piglet models) is needed. This latter study should include analysis of possible
local effects on the gastrointestinal tract and on a possible reduction in the bioavailability of nutrients
(minerals and vitamins) that are normally contained in food for infants. Human data (epidemiological,
clinical studies and case reports, where available) should be included in the evaluation. It is possible to
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deviate from the recommended testing described in this guidance provided that scientiﬁc justiﬁcation is
given. The general principles underpinning the risk assessment performed according to the guidance
or recommendations established by the different EFSA panels and units and prevailing legislations
should be applied.
For substances not intentionally added to food for infants of this age group, the EFSA SC concludes
that their presence in food for infants should be avoided as much as possible. The EFSA SC
furthermore considered that current knowledge of the ontogeny of the metabolic and excretory
pathways permits now to predict the toxicokinetic behaviour of substances if their metabolism in the
adult is known. Even if their metabolic fate is not known in detail, the overall potential impact of the
toxicokinetic variability in infants can be addressed by using an additional kinetic UF to account for the
differences between the adult population and the infants, in particular the very young ones. However,
the EFSA SC is of the opinion that general quantitative and qualitative predictions of adverse effects in
infants of this age group cannot be made and that the uncertainty surrounding the toxicodynamic
variability in infants of this age group does not allow identiﬁcation of appropriate additional UFs.
Therefore, additional considerations on a case-by-case basis are needed to decide whether there is a
health concern. In case studies on neonatal animals are available, these are expected to address the
variability discussed above.
Risk assessment of substances in food for infants
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1. Introduction
1.1. Background and Terms of Reference as provided by the European
Commission
Background
The composition of foods intended for infants and young children is regulated at European Union
(EU) level and such rules include requirements concerning the use and/or presence of substances such
as food additives, pesticide residues, contaminants and substances migrating from food contact
materials in those foods.
Adopting legal provisions on those matters that are in line with the current scientiﬁc knowledge
requires a comprehensive evaluation to be carried out by the European Food Safety Authority (EFSA)
on a number of aspects, including the appropriateness of health-based guidance values (HBGV) for
infants below 16 weeks of age.1
Relevant legal framework
FOOD ADDITIVES IN FOOD FOR INFANTS AND YOUNG CHILDREN
The use of food additives is regulated by Regulation (EC) No 1333/20082 on food additives. Only
food additives that are included in the Union list, in particular in Annex II to that regulation, may be
placed on the market and used in foods under the conditions of use speciﬁed therein. Some of these
are speciﬁc uses of food additives in food destined for infants and young children (food category 13.1)
including uses in food/formulas for infants from birth onwards.
PESTICIDES IN FOOD FOR INFANTS AND YOUNG CHILDREN
Regulation (EU) No 609/20133 on food intended for infants and young children, food for special
medical purposes, and total diet replacement for weight control foresees that the speciﬁc requirements
on pesticides for infant formula, follow-on formula, processed cereal-based food, baby food and food
for special medical purposes developed to satisfy the nutritional requirements of infants and young
children should be updated regularly and include, inter alia, provisions to restrict the use of pesticides
as much as possible [Article ll (l)(b)].
CONTAMINANTS IN FOOD FOR INFANTS AND YOUNG CHILDREN
The EU rules ensure that food placed on the market is safe to eat and does not contain
contaminants at levels which could threaten human health. In order to protect public health, and
speciﬁcally the vulnerable group of infants and young children, strict maximum levels are established
for certain contaminants in foods for infants and young children in the frame of Regulation (EEC)
No 315/934.
FOOD CONTACT MATERIALS FOR INFANTS AND YOUNG CHILDREN
Food comes into contact with many materials and articles during its production, processing,
storage, preparation and serving, before its eventual consumption. Such materials and articles are
called Food Contact Materials (FCMs). FCMs should be sufﬁciently inert so that their constituents
neither adversely affect consumer health nor inﬂuence the quality of the food. To ensure the safety of
FCMs for consumers including infants and young children, speciﬁc migration limits are established for
certain substances, for example in the frame of Regulation (EU) No 10/20115.
Terms of Reference
In accordance with Article 29(1)(a) of Regulation (EC) No 178/20026, the European Commission
requests EFSA to provide a scientiﬁc opinion on scientiﬁc and technical guidance for the risk
assessment of substances – food additives, pesticide residues, contaminants and substances migrating
1 Opinion of the Scientiﬁc Committee on Food on the applicability of the ADI (Acceptable Daily Intake) for food additives to
infants (expressed on 17/9/1998); Opinion of the Scientiﬁc Committee for Food on: A maximum residue limit (MRL) of
0.01 mg/kg for pesticides in foods intended for infants and young children (expressed on 19/9/1997) and Further advice on
the opinion of the Scientiﬁc Committee for Food expressed on the 19 September 1997 on a Maximum Residue Limit (MRL) of
0.01 mg/Kg for pesticides in foods intended for infants and young children (expressed on 4/6/1998).
2 OJ L 354, 31.12.2008, p. 16.
3 OJ L 181, 29.6.2013, p. 35.
4 OJ L 037, 13.2.1993, p. 1.
5 OJ L 12, 15.1.2011, p. 1.
6 OJ L 31, 1.2.2002, p. 1.
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from food contact materials – present in food intended for infants below 16 weeks of age. In
particular, EFSA is requested to provide advice to the European Commission on the generic criteria
and/or requirements that need to be considered by EFSA when performing the risk assessment of
substances present in food intended for infants below 16 weeks of age taking into account the
relevant provisions of the entire above-mentioned legal framework.
1.2. Interpretation of the Terms of Reference
The Terms of Reference require a framework applicable to all relevant working areas of EFSA.
Therefore, the EFSA Scientiﬁc Committee (SC) will prepare a guidance for the risk assessment of
substances in food intended for infants below 16 weeks of age, taking into particular consideration the
procedures to derive HBGV.
1. The term ‘infants below the age of 16 weeks’ is used to describe the particular infant
subpopulations where HBGV such as acceptable daily intake (ADI), tolerable daily intake (TDI) or acute
reference dose (ARfD) have traditionally not been considered applicable. This follows the earlier
conclusions by the former EU Scientiﬁc Committee on Food (SCF) and the World Health Organization
(WHO) that HBGVs do not apply to populations of infants below the age of 16 and 12 weeks,
respectively.
2. The rationale for considering and deﬁning a cut-off value for the age from when a HBGV may
apply is complex. It includes different considerations:
• Physiology: maturation of the different physiological processes and organs in the body is
completed at different ages, and the time frame may be extremely variable between individuals.
Moreover, this population presents a great variability because differences between gestational
age (GA) and chronological age may be present (e.g. whether the child is born preterm or at
term; the chronological age may not be representative of the actual development).
• Nutrition: diet changes with age after birth, from restricted to milk in the ﬁrst months of age to
a more complex one with the introduction of complementary feeding over time.
The EFSA SC considered that the respective SCF and WHO conclusions appear to be pragmatic
rather than scientiﬁcally based. Therefore, for the purpose of this guidance, the term ‘infants below
the age of 16 weeks’ is used to describe the particular infant subpopulations where HBGV have
traditionally not been considered applicable. This population includes preterm neonates receiving
enteral feeding.
3. The guidance should clarify the issues and information requirements that need to be considered
when performing a risk assessment of substances in food intended for the population of interest. As
speciﬁed in the request from the Commission, the Risk Assessment guidance offered is expected to
apply to assessing potential risks from food additives, pesticide residues, contaminants and food
contact materials. The principles outlined in this guidance may also apply to the risk assessment of
other substances which may be added to or are present in food intended for infants below 16 weeks
of age.
4. The guidance should consider the physiological and developmental aspects that are speciﬁc for
infants below 16 weeks of age, with particular attention to the latest scientiﬁc developments in the
ﬁeld. The physiological processes and organ systems to be included are the gastrointestinal tract, the
metabolic and renal capacities relevant for the elimination of chemicals, the immune-, endocrine- and
reproductive systems, and the nervous system including the brain and brain barriers.
5. The guidance focusses on the oral (excluding parenteral) route of exposure because the Terms
of Reference relate to substances present in food.
6. The guidance should address speciﬁc experimental systems that would be appropriate to
characterise the hazard of substances present in food intended for infants below 16 weeks of age.
As regards how to perform an adequate risk assessment for a population of this age, the following
points will be discussed in this guidance:
• What makes this population different from the older ones?
• What kind of relevant information can be retrieved from the currently available data from
biological experimental studies?
• What kind of data is needed?
• What methodology can be used for risk assessment for this age group? Can a tiered approach
deﬁning successive steps of knowledge be applied? Would additional uncertainty/safety factor
(s) be required?
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1.3. Additional information
The EFSA SC considers that the application of this guidance document is unconditional for EFSA
and for all parties submitting assessments of substances present in food intended for infants below
16 weeks of age to EFSA for peer-review (EFSA Scientiﬁc Committee, 2015).
2. Data and methodologies
Literature searches were performed in Web of Science (http://wok.mimas.ac.uk/) and PubMed
(http://www.ncbi.nlm.nih.gov/pubmed/) to identify publications in the public domain in the following
areas relevant to the developing infant.
• Toxicology
• Nutritional needs
• Physiological and biochemical considerations
 Physiology of the gut Metabolic and excretory capacities relevant for the elimination of chemicals The nervous system, including brain and brain barriers The immune system The male and female reproductive systems The endocrine system
Comprehensive reviews covering the above areas were identiﬁed in order to recognise recent
developments since the latest comprehensive assessments of infant toxicology and development by
national and international authorities and agencies. The periods covered ranged from January 2012 to
February 2016 and the searches were performed in Web of Science. The search limits were document
type = review and search terms in title. The search terms combined were ‘intestin*’ OR ‘gastro*’ AND
‘development*’ OR ‘infant’ OR ‘neonat*’ (retrieved 98; selected 5); ‘metabolism’ OR ‘cytochrome’ OR
‘CYP*’ OR ‘glucuronidation’ OR ‘glucuronosyl*’ OR ‘sulfation’ OR ‘sulphation’ OR ‘sulfonyl*’ OR
sulphonyl*’ OR ‘acetylation’ OR ‘conjugation’ OR ‘glutathione OR ‘transporter’ or ‘clearance’ OR ‘ADME’
AND ‘development*’ OR ‘ontogeny’ OR ‘infant’ OR ‘neonat*’ (retrieved 121; selected 10); ‘brain’ AND
‘development*’ OR ‘infant’ OR ‘neonat*’ (retrieved 256; selected 21); ‘immun*’ AND ‘development*’ OR
‘infant’ OR ‘neonat*’ (retrieved 289; selected 14); ‘reproduct*’ OR ‘gonad*’ OR ‘sexua*’ OR ‘endocrin*’
AND ‘development*’ OR ‘infant’ OR ‘neonat*’ (retrieved 105; selected 25). The selection criteria
included coverage of the perinatal or post-natal period and relevance to the assessment. Additional
primary references of particular relevance were identiﬁed by the working group members (up to May
2016).
In addition, publicly available guidance documents and reports produced by committees and
international authorities such as the Joint FAO-WHO Expert Committee on Food Additives (JECFA),
Scientiﬁc Committee on Food (SCF), EFSA and the European Medicines Agency (EMA) that were
relevant to risk assessment of substances in food intended for infants were considered.
A draft of this document Guidance underwent a public consultation from 20 February to 31 March
2017. The comments received were considered and have been incorporated where appropriate.
3. Approach taken to develop this guidance
3.1. Risk assessment of substances present in food intended for infants:
past and current approaches
A Food and Agriculture Organization (FAO)/WHO meeting on additives in baby foods was convened
in 1971, and its draft report was subsequently modiﬁed and adopted by JECFA (FAO/WHO, 1972). The
report made an arbitrary distinction between children aged less than 12 weeks and older children, and
considered it prudent that food intended for infants under 12 weeks of age should not contain any
additives at all. However, if it were deemed necessary to use additives in food intended for young
infants, JECFA concluded that ‘particularly for infants under 12 weeks, toxicological investigations
should be more extensive and include evidence of safety to young animals’. JECFA also concluded that
‘the establishment of acceptable residue levels of pesticides or other contaminants likely to be present
in milk and cereals for infant foods should be based on toxicological evaluation in very young animals’
(FAO/WHO, 1972).
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These concepts were further elaborated by the WHO in (IPCS, 1987) where the need for
toxicological studies covering the corresponding period of life and the limitation of current testing
approaches were noted for cases when young infants are a target population for an additive. This
WHO report stated that ‘scientiﬁc evidence indicates that newborns and very young children are
particularly sensitive to the harmful effects of foreign chemicals’ due to, inter alia, ‘immaturity of
enzymatic detoxifying mechanisms, incomplete function of excretory organs, low levels of plasma
proteins capable of binding toxic chemicals, and incomplete development of physiological barriers such
as the blood-brain barrier. Moreover, there appears to be a general vulnerability of rapidly growing
tissues, which is particularly important with regard to the developing nervous system’ (IPCS, 1987).
In a workshop organised by the ILSI Europe Acceptable Daily Intake Task Force on the applicability
of the ADI to infants and children held in 1997, the differences between infants or children and adults
from susceptibility and food intake points of view and the adequacy of testing methods and safety
factors were discussed (Larsen and Pascal, 1998). Among the recommendations, it was proposed that
no special safety factors, and consequently no special ADIs, should be used for infants and children
and that any evidence of enhanced sensitivity of this age group to a particular food additive must drive
the derivation of the ADI. However, because the usual toxicological test battery does not mimic the
human situation with the ingestion of infant formula, the ADI should not be considered directly
applicable to infants below 12 weeks of age.
The SCF (1998) expressed an opinion on the applicability of the ADI for food additives to infants.
The SCF noted that the scientiﬁc support for the 12 week cut-off was not presented in any details in
the 1972 JECFA report (FAO/WHO, 1972). While acknowledging the importance of the physiological
immaturity of many of the organ systems in the ﬁrst weeks and hence an enhanced vulnerability, the
SCF advocated a 16-week cut-off because of the nutrition habits up to that age (i.e. mother’s milk or
infant formulae intended for use as the sole source nutrition for infants). Furthermore, the standard
animal studies recommended by JECFA and the SCF to assess food additives do not address the
exposure situation (i.e. exclusive feeding via infant formula, relevant to this speciﬁc age group).
A systematic analysis of the scientiﬁc principles to be considered in assessing health risks in children
from exposures to environmental agents during distinct stages of development, is reported in (IPCS,
2006). In 2009, the WHO re-iterated its recommendations that ‘very young infants are a particularly
sensitive subgroup because their metabolic capacities are not yet fully developed’ and that ‘health-
based guidance values are not considered applicable to infants under the age of 12 weeks who might
be at risk at lower levels of exposure. Accordingly, risk characterisation of exposure of such infants to
chemicals (e.g. in infant formula or occurring as contaminants) has to be considered on a case-by-case
basis’ (IPCS, 2009).
At its 79th meeting (FAO/WHO, 2014), JECFA evaluated three food additives intended for use in
infant formulae and reported general considerations for use of the margin of exposure (MOE) for the
evaluation of such food additives. JECFA noted that the ADI concept does not apply to infants up to the
age of 12 weeks because they might be at risk at lower levels of exposure compared with older age
groups and that risk characterisation for very young infants has to be considered on a case-by-case
basis. The report noted that, while reproductive and developmental studies address possible impacts of
in utero and lactational exposure on neonates, studies involving direct oral administration to neonatal
animals are required for the evaluation of additives to be used in infant formulae. If the food additive is
intended for use in infant formula at relatively high levels (e.g. 0.1% or greater), then conducting
toxicological studies in neonatal animals at doses two or more orders of magnitude greater than the
anticipated human exposure, which is the approach commonly taken for food additives, may not be
feasible. Therefore, JECFA considered the MOEs between the respective no-observed-adverse-effect
level (NOAEL) and the estimated daily exposures to the food additives, and described toxicological and
exposure considerations that need to be taken into account in interpreting the MOE (Table 1).
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3.2. Working deﬁnitions for stages in early human development for this
guidance
Several classiﬁcations of the paediatric population into age categories exist and are to some extent
arbitrary due to considerable overlap in developmental (e.g. physical, physiological, cognitive and
psychosocial) issues across the age categories. From an EU legislative consideration,7 the term ‘infant’
means a child under the age of 12 months and ‘young child’ means a child aged between 1 and
3 years. For the purpose of this guidance, the population of interest corresponds to infant
subpopulations where health-based guidance values such as ADI have traditionally not been
considered applicable, herein referred to as ‘infants below 16 weeks of age’. Concerning the stage of
physiological development, it is to be noted that this population includes term and preterm neonates
(Figure 1).
Table 1: Toxicological and exposure considerations to be taken into account in interpreting the
margin of exposure (MOE) in the evaluation of food additives used in infant formula, as
proposed by JECFA
Considerations related to the toxicological point of departure(a)
Absorption, distribution, metabolism and excretion in the neonatal organism
Overall toxicological proﬁle of the substance (including identiﬁcation of critical effects)
Potential effects of exposure during life stages in experimental animals of relevance to human infants
Relevance for the human infant of the neonatal animal models used in toxicological testing
Adverse effects: identiﬁed in studies in neonatal animals or is the NOAEL the highest dose tested?
Design and outcome of any clinical studies conducted with infants
Reports of adverse reactions in post-marketing surveillance
Considerations related to the dietary exposure assessments
Formula is the only source of nutrition for the ﬁrst 12 weeks of life in non-breastfed infants
The additive is used at the maximum proposed level
An energy density of 67 kcal/100 mL (280 kJ/100 mL) is used to convert energy to the volume of formula
ingested daily
High infant formula consumption is derived from 95th percentile energy intakes
Variability of exposure among infants is small
Duration of exposure is for a limited time, and exposure decreases on a body weight basis during the exposure
period
NOAEL: no-observed-adverse-effect level.
(a): The point of departure (PoD) is equivalent to the reference point (RP) used by EFSA.
7 REGULATION (EU) No 609/2013 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 12 June 2013 on food intended for
infants and young children, food for special medical purposes, and total diet replacement for weight control and repealing
Council Directive 92/52/EEC, Commission Directives 96/8/EC, 1999/21/EC, 2006/125/EC and 2006/141/EC, Directive 2009/39/EC
of the European Parliament and of the Council and Commission Regulations (EC) No 41/2009 and (EC) No 953/2009.
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The continuous vertical line represents fertilisation and the dotted vertical line represents normal
term birth. Breast feeding may be exclusive or involve infant formula. Abbreviation: rec.,
recommended.
4. Nutritional needs of infants
4.1. Feeding pattern of term infants during the ﬁrst months of life
The European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) advises
that exclusive breastfeeding for around six months is a desirable goal for nutrition of infants (Agostoni
et al., 2010). Similarly, the WHO recommends that ‘Exclusive breastfeeding for 6 months has many
beneﬁts for the infant and mother’ and ‘Around the age of 6 months, an infant’s need for energy and
nutrients starts to exceed what is provided by breast milk, and complementary foods are necessary to
meet those needs’ (WHO, 2001, 2016) (see also Kramer and Kakuma, 2001). If breastfeeding is not
possible, infants should receive an infant formula. Regulation (EU) No 609/20138 deﬁnes infant
formula as ‘food intended for use by infants during the ﬁrst months of life and satisfying by itself the
nutritional requirements of such infants until the introduction of appropriate complementary feeding’
[Article 2(2)(c)].
In its Scientiﬁc Opinion on the appropriate age for introduction of complementary feeding of
infants, EFSA concluded that the introduction of complementary food into the diet of healthy term
infants in the EU between the age of 4 and 6 months is safe and does not pose a risk for adverse
health effects (EFSA NDA Panel (2009). Therefore, in non-breastfed infants, infant formula should
represent the sole source of nutrition until at least the age of four months. The essential composition
of infant formula is laid down in EU law. Currently, Commission Directive 2006/141/EC9 applies but will
be replaced by Commission Delegated Regulation (EU) 2016/12710, applicable from 22 February 2020,
except for infant formula and follow-on formula manufactured from protein hydrolysates, to which it
shall apply from 22 February 2021.
Figure 1: Key life stages
8 Regulation (EU) No 609/2013 of the European Parliament and of the Council of 12 June 2013 on food intended for infants and
young children, food for special medical purposes, and total diet replacement for weight control and repealing Council
Directive 92/52/EEC, Commission Directives 96/8/EC, 1999/21/EC, 2006/125/EC and 2006/141/EC, Directive 2009/39/EC of
the European Parliament and of the Council and Commission Regulations (EC) No 41/2009 and (EC) No 953/2009, OJ L 181,
29.6.2013, p. 35.
9 Commission Directive 2006/141/EC of 22 December 2006 on infant formulae and follow-on formulae and amending Directive
1999/21/EC.
10 Commission Delegated Regulation (EU) 2016/127 of 25 September 2015 supplementing Regulation (EU) No 609/2013 of the
European Parliament and of the Council as regards the speciﬁc compositional and information requirements for infant formula
and follow-on formula and as regards requirements on information relating to infant and young child feeding.
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The ﬁrst months of life are characterised by high requirements of energy intake per kg bw due to
the rapid growth rate and increase in body weight (Table 2). While energy intake per kg bw peaks in
the ﬁrst 2 months and decreases afterwards, total energy intake (kcal/day) increases during infancy.
Similar changes occur in consumption of breast milk or infant formula when they are the sole source of
food for infants in the ﬁrst 4–6 months of life.
4.2. Consumption data in use by EFSA for the risk assessment of
substances present in food for term infants
For infants under 6 months of age, EFSA based its exposure estimates to contaminants present in
breast milk and infant formula on standard values for 3-month-old infants using a weight of 6.1 kg, an
estimated average daily consumption of 800 mL and a high consumption of 1,200 mL (e.g. EFSA
CONTAM Panel (2010). These ﬁgures were derived from the following sources and considerations:
‘according to the Institute of Medicine of the U.S. National Academies of Sciences (IOM), average
breast milk consumption is about 750–800 g/day (range: 450–1,200 g/day) for the ﬁrst 4–5 months of
life (IOM, 1991). Infant birth weight and nursing frequency have been shown to inﬂuence consumption
(IOM, 1991). The WHO related breast milk consumption to body weight rather than age with an
estimated 125 mL/kg body weight (bw) or 763 mL/day for a 3-month-old child weighing 6.1 kg
(Onyango et al., 2002). According to the German DONALD study, mean consumption of infant formula
for a 3-month-old child weighing on average 6.1 kg, was 780 mL/day with a 95th percentile
consumption of 1,060 mL/day (Kersting et al., 1998). The DARLING study, performed in the USA in the
early 1990s, points out signiﬁcant differences in milk iccntake between formula-fed infants and
breastfed infants: mean milk intake was lower at 3 months (812  133 mL vs 905  162 mL) and
6 months (769  171 mL vs 941  238 mL) in breastfed compared with formula-fed infants,
respectively (both p < 0.05) (Heinig et al., 1993).
In 2011, EFSA started to use data from the EFSA Comprehensive European Food Consumption
Database for the assessment of dietary exposure to hazardous chemicals. This database includes food
consumption data for infants up to and including 11 months. In 2011, information on infants were
available from only two Member States (Italy and Bulgaria), whereas, in 2015, food consumption data
from an additional four Member States (Germany, Finland, Denmark and the UK) were added.
Consumption statistics of infant formula (liquid) in infants in the ﬁrst year of life from the EFSA
Comprehensive European Food Consumption Database are reported in Table 3. Food consumption
data on infants below 4 months are only available from one survey carried out in Bulgaria, with a 95th
percentile of consumption equal to 1,120 mL/day (274.2 g/day per kg bw) for consumers of infant
formula. Dietary surveys on infants are currently ongoing in different EU countries within the EU Menu
project and their data will be included in the Comprehensive Database as soon as they are made
available to EFSA.
At present, data for infants in use by EFSA do not allow time course quantitation of formula
consumption during the ﬁrst 16 weeks of life.
Table 2: Reference values for body weight and energy requirements of infants in the ﬁrst months
of life (taken from EFSA NDA Panel, 2013)
Age Body weight(a)
Average energy
requirement
Average energy
requirement
Months
Kg kcal/kg bw per day kcal/day
Boys Girls Boys Girls Boys Girls
0 to < 1 --- 109 103 359 329
1 to < 2 4.5 4.2 112 107 505 449
2 to < 3 5.6 5.1 95 92 531 472
3 to < 4 6.4 5.8 78 79 499 459
4 to < 5 7.0 6.4 78 79 546 503
bw: body weight.
(a): 50th percentile of WHO growth standards.
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4.2.1. Formula consumption over time in healthy non-breastfed term infants
during the ﬁrst 16 weeks
Fomon et al. (1971) reported daily formula consumption in healthy infants throughout the interval
of 8–111 days of life (Fomon et al., 1971). The study was carried out between 1966 and 1970, in a
sample of 142 Caucasian full-term infants (65 males and 77 females), in a university community in
Iowa, USA. Ready-to-feed cow’s milk based formula was delivered to the participating families in 120
or 240 mL units to supply for 48–72 h; bottles including unconsumed portions were collected and
re-weighed. The energy density of the formula (67 kcal/100 mL) was similar to the energy density of
breast milk as reviewed by the EFSA NDA Panel (2014) with 65 kcal/100 g and ﬁts well into the
60–70 kcal/100 g range required for infant formula by the present Commission Directive (Commission
Directive 2006/141/EC) and the Commission Delegated Regulation (EU) 2016/127, and as recently
proposed by the EFSA NDA Panel (2014).
During days 8–111, daily formula consumption (mL/day) in high consumers (P90) increased up to a
maximum of around 1,000 mL/day, which was achieved in boys by the age of 28–41 days and in girls
by the age of 84–111 days. Formula consumption related to body weight in high consumers (P90)
peaked by the end of the ﬁrst month at about 200 mL/kg bw (Table 4). Consumption at P95 was not
reported for this study sample. However, for a larger sample of this study (380 boys and 340 girls),
energy intake per kg bw during the ﬁrst 8–111 days of life was reported including P95 values (Fomon,
1993). Using the energy density of the formula applied in the study (67 kcal/100 mL), it is possible to
recalculate formula consumption as mL/kg bw at P95 in the subsample of the 142 infants from which
the original consumption data are available (Fomon et al., 1971) (Table 4). The recalculated P95
consumption values reach a peak by the end of the ﬁrst month of life of about 220 mL/kg bw in both,
boys and girls. It can be assumed that this approach is robust, as the recalculation of the P90 (and
P50) formula consumption per kg bw from the reported P90 (P50) energy intake resulted in almost
identical consumption values as reported originally for the subsample (Table 4).
4.2.2. Simulating a consumption time course in healthy non-breastfed term
infants during the ﬁrst 16 weeks with data used by EFSA
While the Fomon data can provide evidence for choosing the 1-month-old infant to reﬂect high
consumption in the ﬁrst 16 weeks of age, it is not clear whether the data from a study carried out
Table 4: Consumption of formula in healthy term infants during the ﬁrst 16 weeks of life
Age (days) 8–13 14–27 28–41 42–55 56–83 84–111
Boys (n = 65)
mL/day
P50(a) 573 696 774 790 846 890
P90(a) 741 865 988 1,028 1,033 1,030
mL/kg bw per day
P50(a) 166 181 172 161 148 137
P90(a) 208 214 209 198 178 155
P95(b) 216 222 213 202 179 164
Girls (n = 77)
mL/day
P50(a) 558 657 695 721 741 791
P90(a) 745 757 854 855 909 975
mL/kg bw per day
P50(a) 160 169 159 153 137 133
P90(a) 208 197 195 182 164 –
P95(b) 213 218 215 198 180 166
bw: body weight.
(a): Daily measurements of liquid formula consumption, 142 infants (65 boys and 77 girls), study period: 1966–1970 (Fomon
et al., 1971).
(b): Recalculated from reported energy intake (kcal/kg bw) and a mean energy density of 67 kcal/100 mL formula; energy intake
data are from a larger group of infants (boys: n = 380; girls: n = 340) (Fomon, 1993), which included the sample for which
original consumption data are presented.
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50 years ago represent current consumption habits. In the long-term observational German DONALD
study, 3-day weighed dietary records were collected between 1990 and 1996 in infants aged 3, 6, 9
and 12 months (Kersting et al., 1998). In the diet records, formula consumption was reported as
(instant) powder. In the group of consumers of formula (n = 59) at the age of 3 months, the P95
value was 24.4 g/kg bw (maximum 24.6 g/kg bw) and a mean  SD of 17.1  4.7 g/kg bw, P50 not
being reported.
To overcome the problem of different methods used to assess formula consumption in the older
study where ready-to-feed bottles were administered (Fomon et al., 1971) and the newer study where
powder amount per bottle to be mixed with water was recorded (Kersting et al., 1998), information on
today’s practice of formula preparation from powder is needed.
Recently, EFSA carried out a search of the Global New Products Database (GNPD) to collect
information on preparation instructions on the labels of infant formulae introduced on the European
market in the last 24 months (111 products from 13 countries). For most products, one scoop of infant
formula powder is to be used for 30 mL of water and the use of the 4.3 g of powder per spoon is the
most frequently mentioned scoop size. If this amount (4.3 g) is added to 30 mL of water, it
corresponds to 12% (1:8) of the ﬁnal liquid infant formula. In a recent market search of package
instructions of infant formula in Germany (June 2016; eight products, ﬁve companies), a similar ratio
was found referring to feeding the youngest infants (around 1-month-old).
A recalculation of the potential liquid formula consumption (12%) from the P95 powder
consumption 24.4 g/kg bw at the age of 3 months results in a consumption of 195 mL/kg bw
(Table 5) which is 18% higher than reported in the Fomon study 50 years ago at the age of around
3 months (Table 4). Starting with this recalculated newer liquid consumption ﬁgure at the age of
3 months and using the same course of consumption as in the earlier study, the peak at age 1 month
is about 260 mL/kg bw per day. As P50 values of powder consumption (per kg bw) at age 3 months
were not reported in the newer study (Kersting et al., 1998), a similar higher consumption by 18%
was also assumed for the P50 level and a time course was estimated accordingly (Table 5).
Taking into account all of the available information, the EFSA SC recommends values of 200 and
260 mL/kg bw per day as conservative mean and high level consumption values to be used for
performing the risk assessments of substances which do not accumulate in the body present in food
intended for infants below 16 weeks of age. These values are derived from data for infants aged
2–4 weeks, when formula consumption is highest, expressed on a body weight basis.
For assessing the exposure to substances with a long half-life and therefore accumulate in the
body, it may be appropriate to select consumption values representing a longer period of formula
feeding. For example, consumption values for infants of around 2 months of age (56–83 days)
(Table 5) could be used, i.e. around 170 (P50) or 210 (P95) mL/kg bw.
4.2.3. Feeding of preterm infants
The present-day nutrition guidance for preterm infants aims to achieve growth similar to fetal
growth coupled with satisfactory functional development (Agostoni et al., 2010).
ESPGHAN (2010) recommends a ‘reasonable upper limit’ of ﬂuid intake of 200 mL/kg bw (range
135–200 mL/kg bw) for enteral intake of stable-growing preterm infants up to a weight of 1,800 g
Table 5: Estimated consumption of formula using old consumption data during the ﬁrst 16 weeks of
life (Table 4) and newer data on formula consumption at 3 months of age (Kersting et al.,
1998)
Age (days) 8–13 14–27 28–41 42–55 56–83 84–111
mL/kg bodyweight per day
Boys
P50(a) 196 214 203 190 175 162
P95(a) 254 261 251 238 211 195(b)
Girls
P50(a) 189 199 188 180 162 157
P95(a) 251 257 253 233 212 195(b)
(a): Estimated as 18% higher than the old data throughout the time course of the ﬁrst 16 weeks of life based on the 18%
higher consumption at P95 in the newer study at the age of 3 months.
(b): As boys and girls were not separated in the newer study, the P95 value at age 3 months was applied for both sexes.
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(Agostoni et al., 2010). This ESPGHAN recommendation (135–200 mL/kg bw) was conﬁrmed for the
‘micropreterm infant’ (< 30 weeks gestation, < 10th P birth weight) (Tudehope et al., 2013). For the
very low birth weight neonate (< 1,000 g), full enteral feeding with 150–180 mL/kg bw was
recommended, and should be achieved by about 2 weeks in < 1,000 g birth weight, and by about
1 week in 1,000–1,500 g birth weight (Dutta et al., 2015).
Because these consumption values are lower than those for term infants in Table 5, application of
the high consumption value of 260 mL/kg bw in infants below 16 weeks of age would also cover the
potential high consumption rates of preterm infants on enteral (formula) feeding as recommended at
present.
5. The developing infant: physiological and biochemical considerations
Most organ and organ systems lack structural or functional maturity at birth. The degree of
immaturity may be aggravated due to prematurity, intrauterine growth retardation or any potential
pathological condition affecting the infant. Immaturity of physiological processes and organ function
predispose neonates to altered toxicokinetics and toxicodynamics, leading to potentially enhanced
sensitivity of infants towards substances present in food.
Organ maturation is rapid in the post-natal period, and as a result can yield a high degree of both
interindividual and intraindividual variability in the infant population, which might be greater than later
in life.
Data are available (ICRP, 2002) from which the relative organ weights can be taken for a newborn
compared to the adult. For example, the relative liver weight is 37 g/kg bw in newborns and 25 g/kg
bw in adults, the relative weight of the kidneys is 7.1 g/kg bw in newborns and 4.3 g/kg bw in adults.
The greatest difference exists for the relative brain weight which is 108 g/kg bw in the newborn and
20 g/kg bw in the adult.
The WHO (IPCS, 2006) reviewed extensively the aspects of organ maturation in infants. These are
summarised below, with a particular focus on recent developments in the areas that are pertinent to
the risk assessment of substances present in food intended for infants.
5.1. The developing gut
There are reviews available on the intrauterine development of the gastrointestinal tract (Grand
et al., 1976; Wells and Spence, 2014). The development is a complex process to which all three germ
layers contribute. Among them, and most important, is the endoderm-derived epithelium, which
houses specialised intestinal stem cells, that are important for the renewal of the cellular epithelium
during the turn-over of the mucosal layer (Sato and Clevers, 2013). Smooth muscle, vasculature and
lymphatic are mesoderm-derived, and the nervous system of the gastrointestinal wall has its origin in
ectodermal tissue. Besides its role in digestion and absorption of nutrients, the intestine is also a major
lymphoid organ through the gut associated lymphoid tissue, which is responsible for the immune
tolerance to dietary antigens.
Recently, the colonisation with microbiota of the intestinal tract has become a ﬁeld of interest also
for the post-natal development of the structure and function of the intestine (Di Mauro et al., 2013).
However, limited knowledge is available concerning the post-natal development of the human
gastrointestinal tract, and whether it is affected by differences in the microbiota.
Local effects in the gastrointestinal tract and absorption and systemic fate of a substance may
depend upon its release from the ingested organic matrix, local pH, transit time, size of the absorptive
surface or its metabolism by the gastrointestinal wall and also by the bacterial microbiome.
Gastric emptying and intestinal motility
The functional gastric capacity of infants is quite limited. It ranges from 38 to 76 mL in term
neonates (Zangen et al., 2001). The coordination of antral contractions is developing after birth,
resulting in a marked increase in gastric emptying during the ﬁrst week of life (Gupta and Brans,
1978). Similarly, increases in the frequency, amplitude, and duration of propagating contractions have
been observed to occur in preterm infants (Berseth, 1989; Ittmann et al., 1992). In most studies, the
emptying pattern is exponential and can be ﬁtted using the Elashoff model (Elashoff et al., 1982). In
preterm infants (24–34 weeks), gastric half-emptying time (T1/2) is in the range of 70 min for formula
and 35 min for human milk. In full-term infants, data are scarce and T1/2 is in the range of 80 min for
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formula. Many factors, including caloric density, may affect emptying rate (reviewed by Bourlieu et al.,
2014).
The small bowel motility patterns are poorly developed before 28 weeks of gestation, showing a
disorganised motility pattern between 27 and 30 weeks, progressing to more mature migrating
myoelectric complexes by 33–34 weeks of gestation (Berseth, 1996). Consequently, total transit time is
longer in preterm than in term infants. However, interindividual variance is high and sample sizes are
small (Bode et al., 2004).
Gastric secretion and digestive enzymes
Gastric acid secretion is active at birth even in very preterm neonates (GA = 24 weeks), and the
gastric pH decreases below 4 in the ﬁrst day of life (Avery et al., 1966). However, the high buffering
capacity of human milk and formulae stabilises the gastric pH in the range 5–6; this pH level lasts longer
as the meal frequency increases. The pH of gastric content after ingestion of human milk or formulae is
optimal for gastric lipase, but not for pepsin activity (Armand et al., 1996). However, extensive proteolysis
occurs in the term infant’s stomach during the ﬁrst two weeks of life (Dallas et al., 2014).
The secretion of gastric and pancreatic enzymes is not developed to adult levels at birth. In infants,
secretion outputs and enzyme activity levels mature at very different rates: gastric lipase activity
already reaches adult levels by 3 months (Menard et al., 1995), whereas pancreatic a-amylase only
does so after 3 years of age (Zoppi et al., 1972). Of note, gastric lipase reaches about 75% of adult
maximum levels in preterm newborns (Roman et al., 2007). By 1 month post-partum, term and
preterm infants’ trypsin activity is similar to that of 2–6 years old children (Lebenthal and Lee, 1980).
Pancreatic secretion rate of ﬂuids is generally higher in preterm than in term infants. This was also
reported for enzyme production in infants of the same post-natal age (Zoppi et al., 1973). Duodenal
pH is in the range 5.2–7.6. In newborn infants, bile salt metabolism is active, but immature owing to a
not yet fully developed conjugation capacity and slower transport into the intestinal lumen (Poley
et al., 1964; Suchy et al., 1981). Therefore, the bile salt pool is limited and the primary bile salt
concentration in the duodenum is low (Norman et al., 1972). In contrast, the small intestine of human
infants is mature at birth and can handle the various nutrients (Shmerling, 1976). The intestinal
surface area is even proportionally greater in infants than in adults because of the rapid prenatal small
intestine growth rate (Weaver et al., 1991). Figure 2 provides an overview of the changes in
gastrointestinal structure and function with age.
The analysis of ileocaecal samples in infants aged 10 days to 5 months and fed 150 mL breastmilk/
kg bw per day showed that proteins are almost fully digested and absorbed (Hirata et al., 1965).
Balance studies in moderately premature infants (30–36 weeks of gestation) fed either human milk or
cow’s milk derived formulae have shown that premature infants are also able to digest and absorb
proteins (Senterre, 1976). Similarly, the coefﬁcient of absorption of fat in breastfed infants is about
90–95% at 1 week of age and 96% at 1.5 months of age (Williamson et al., 1978). By contrast, fat
digestion is less efﬁcient with cow’s milk derived formulae as indicated by a 70–85% coefﬁcient of
absorption at 3 months of age (Manson et al., 1999). Fat absorption may be even lower in premature
Figure 2: Overview of the age-dependent changes in gastrointestinal structure and function with age.
Modiﬁed from (Kearns et al., 2003)
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infants (Schmitz, 1977). Despite the slow maturation of pancreatic amylase, most cooked starches
are digested and absorbed almost completely as early as 1 month after birth. However, high intakes
(40 g/day) induced fermentative diarrhoea in 40% of the infants (DeVizia et al., 1975).
Intestinal permeability
Some animal species (e.g. mouse, rat) retain fetal-type enterocytes at birth. These cells present
many cytosolic vacuoles (related to the apical tubular system (ATS)) actively involved in the uptake of
luminal material. In mice and rats, fetal-type enterocytes are completely replaced by mature-type ones
by the end of weaning, a phenomenon called ‘closure’. By contrast, human neonates have mature-type
enterocytes at birth, characterised by an adult-type microvillus enzyme pattern (e.g. sucrase) and the
absence of vacuoles (Moxey and Trier, 1979; Zabielski et al., 2008). The change from fetal-type to
mature-type intestinal epithelium is realised by 18–22 weeks and the ATS is undetectable by 24 weeks
of gestation (Milla and Bisset, 1988). Infants born at 34–37 weeks of gestation achieve a ‘mature’
passive intestinal permeability to lactulose (MW 342; assumed to cross the intestinal wall by a
paracellular route) within 4 days after starting oral feeding. ‘Mature’ intestinal permeability is achieved
earlier in exclusively breastfed than in formula-fed infants (Catassi et al., 1995; Taylor et al., 2009).
Infants born before 34 weeks of gestation have a higher lactulose permeability than term babies.
However, preterm infants show a progressive decrease in lactulose absorption during the ﬁrst week of
oral feeding (Weaver et al., 1984), irrespective of feeding mode (breast milk vs formula) and prebiotic
supplementation (Westerbeek et al., 2011).
Gut microbiota
The microbiome in infants is highly dynamic and differs from the microbiome in adults, which is
stable and resilient. Schematically, soon after birth, the bacterial microbiome switches rapidly from
predominantly facultative anaerobic bacteria towards a diverse community of anaerobes. However, its
composition can be notably affected by the mode of delivery (vaginally vs caesarean section), the
mode of feeding (breast milk microbiome might be its main physiological template), the environment
(from household to geographic location), the host genetics and the use of antibiotics, which may
signiﬁcantly and permanently alter the developing microbiome (Lim et al., 2016). It should be stressed
that the reference compositions of the healthy infant and adult microbiota are still unknown.
In the preterm infant, GA, sex and mode of feeding (mother’s milk or not), as well as the intensive
care unit environment, appear to be the major factors inﬂuencing microbiota development (Cong
et al., 2016). Schematically, preterm infants display a delay in colonisation with typical commensal
bacteria. They show reduced microbiota diversity, reduced levels of strict anaerobes and a high
abundance of Proteobacteria.
5.1.1. Summary
Gastric, pancreatic and biliary functions are not fully mature at birth. However, this does not
preclude term infants thriving on breastfeeding. It may be particularly relevant to the evaluation of
exposure to various chemicals that term neonates display a mature-type intestinal epithelium.
The local effects of a substance on the gastrointestinal tract, its absorption and its systemic fate will
depend upon its release from the ingested organic matrix, local pH, transit time, size of the absorptive
surface or its metabolism by the gastrointestinal wall and by the bacterial microbiome, all parameters
changing during post-natal maturation.
5.2. Ontogeny of the processes involved in the absorption, distribution,
metabolism and excretion of chemicals
5.2.1. Absorption
This guidance focuses on oral exposure, and therefore, the term absorption relates to absorption
from the gastrointestinal tract.
Only a few studies have been published on the oral absorption of drugs and other substances in
infants below 16 weeks of age (Heimann, 1980; Bowles et al., 2010; Batchelor et al., 2014; Batchelor
and Marriott, 2015).
In a series of studies, Heimann investigated the absorption of several therapeutically used drugs
(sulfonamides, phenobarbital, digoxin and b-methyldigoxin) in paediatric patients in relation to their
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age (some days until 1 year) (Heimann, 1980). The amount of absorption, as expressed by the area
under the curve (AUC), was not age dependent, whereas the rate of absorption was slower in
neonates and increased within the ﬁrst year to the values observed in adults. Heimann also
investigated the absorption of L(+)-arabinose and D(+)-xylose. The amount absorbed of D(+)-xylose, a
substance that is taken up through the gastrointestinal wall by active transport, was independent of
the age, whereas the rate of absorption was age dependent. The same ﬁndings were reported by
Heimann for L(+)-arabinose, a substance that is taken up by passive diffusion. Thus, from the ﬁndings
with drugs and some test substances, it can be anticipated that the absorption of substances in
general might be slower in young infants than in older ones but that the amount absorbed is not
dependent on the age.
5.2.2. Distribution
Body composition changes with age and hence the physiological spaces to which substances
distribute can change. The volume of distribution of a substance, which is not congruent with a
physiological space, can change. Factors associated with development such as regional blood ﬂow,
organ perfusion, and cardiac output, and also changes in relative organ weights can inﬂuence
distribution. For example, extracellular and total-body water spaces are larger in neonates and young
infants compared to adults (Friis-Hansen, 1983). Also, the adipose stores might be different whereby
the percentage of fat is less than 20% in neonates and in young infants and increases in the following
months to reach 30% at the age of 9 months. The percentage of extracellular water decreases from
40% in neonates to 30% at 9 months (Figure 3). Details on organ weights and blood ﬂows through
the organs in neonates, infants, children, adolescents and adults are given in several sources (ICRP,
2002; Abraham et al., 2005; Mielke and Gundert-Remy, 2009).
As a consequence of the rising body fat, whereas total body water and extracellular water declines,
it can be predicted that the concentration of water soluble, polar substances in plasma will become
higher and that of fat soluble, non-polar substances in plasma will become lower.
A special case comprises highly plasma protein-bound substances for which altered protein content
and binding may have an inﬂuence on the kinetics of these substances. The quantity of total plasma
proteins (in particular albumin) is reduced during the neonate and young infant period. A higher
concentration of bilirubin in neonates might lead to displacement of protein-bound substances from
the binding site, thus increasing the non-protein-bound fraction. There are some examples in which
this causes an increase in the non-protein-bound fraction of the substance (Ganshorn and Kurz, 1968;
Ehrnebo et al., 1971; Fredholm et al., 1975; Windorfer et al., 1978).
The distribution of a xenobiotic can mechanistically be understood as resulting from passive
diffusion through membranes. The non-protein-bound, free concentration in plasma is in equilibrium
with the free concentration in the tissue (Pelkonen et al., 2008; Smith et al., 2010). Thus, the driving
force is the concentration gradients between the binding of the drug in blood and the resulting free
concentration and the free concentration in the tissue, which depends on the binding of the drug to
tissue components. Depending on the physicochemical properties of the substance and the tissue
composition, different tissue to plasma/blood relationship will be established for a substance. Some
tissues, also the intestinal wall, express transporters that may transport substances into the cells or
out of the cells of the tissue. It is assumed that the activity of the transporters is age-dependent.
However, the paucity of experimental data does not allow drawing ﬁrm conclusions on this issue (Mooij
et al., 2016).
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5.2.3. Metabolism and excretion
The main excretory pathways are via metabolism in the liver and renal excretion by the kidney.
Volatile agents as well as CO2, as an ultimate product of metabolism, may be excreted by exhalation.
Biliary excretion is for most of the substances a minor excretory pathway in Man. Despite the relatively
higher weight of the excretory organs in newborns, their function for the excretion of substances is not
yet at the level of the adults with the exception of a few metabolic pathways.
The ontogeny of transporters, xenobiotic drug metabolising enzymes and renal excretion as well as
their pharmacokinetic consequences in humans have been reviewed extensively, particularly with the
data rich pharmaceutical literature (Renwick et al., 2000; Alcorn and McNamara, 2002; Dorne et al.,
2005; Lee et al., 2012; Valcke and Krishnan, 2013; Doring and Petzinger, 2014; O’Hara et al., 2015).
Mathematical and pharmacokinetic (PK) models such as physiologically based PK (PB-PK) models have
been developed to predict age speciﬁc differences, age speciﬁc uncertainty factors (UFs) and age- and
clearance pathway-speciﬁc infant scaling factors (ISFs) (Renwick et al., 2000; Alcorn and McNamara,
2002; Dorne et al., 2005; Valcke and Krishnan, 2013; Salem et al., 2014).
Metabolism
Metabolism involves two large groups of enzymes catalysing phase I and phase II reactions.
Phase I enzymes catalyse key reactions such as oxidation, reduction and dealkylation (e.g. by
cytochrome P-450) and hydrolysis (e.g. by epoxide hydrolase and esterases).
Phase II enzymes catalyse conjugation such as glucuronidation by uridine diphosphate (UDP)-
glucuronosyltransferase (UGT) isoenzymes (the largest group of phase II enzymes), sulfation by
sulfotransferases, glutathione and methyl conjugation by glutathione-S-transferases and methyl-S-
transferases, amino acid conjugation (e.g. glycine conjugation) and N-acetylation (NAT-1 and NAT-2).
A reduced activity of these enzymes may be responsible for the toxicity syndromes that have been
seen in preterm infants, such as grey baby syndrome with chloramphenicol (UGT2B7), neonatal
jaundice with bilirubin (UGT1A1) and gasping syndrome with benzyl alcohol (glycine conjugation)
(O’Hara et al., 2015).
Discussing the developmental pattern of each enzyme isoform known in humans is beyond the
scope of this guidance document.
Generally speaking, each enzyme isoform for phase I and phase II reactions has a unique pattern
of development; however, the following three groups have been proposed based on expression proﬁles
in human livers (Hines, 2008; van den Anker et al., 2011; de Wildt et al., 2014) (Figure 4).
1) Expression is present during prenatal development with silencing or low level expression
within 1—2 years after birth. Speciﬁc isoforms include CYP3A7, FMO1, SULT1A3/4, SULT1E1,
ADH 1A.
Figure 3: Age-dependent changes in body composition and its inﬂuence on the apparent volume of
distribution for chemicals. Total-body water and extracellular water, expressed as a
percentage of total body weight, is much larger in infants in the ﬁrst 6 months of life
compared to older infants. Modiﬁed from (Kearns et al., 2003)
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2) Expression is at relatively constant levels throughout fetal development and increases post-
natally. Speciﬁc isoforms include ADH1C, ADH1B, CYP2A6, CYP2C9, CYP2C19, CYP2D6,
CYP2E1, FMO3 and SULT2A1. As an example, the major isoforms of human cytochromes P450
are CYP3A isoforms (CYP3A4/CYP3A5/CYP3A7) which contribute to the metabolism of more
than 50% of all marketed drugs and the expression patterns of these isoforms are subjected to
developmental inﬂuence. As CYP3A7 is highly expressed in fetuses, there is a shift in
expression from CYP3A7 to CYP3A4, which occurs within the ﬁrst month after birth. The shift in
expression is associated with a rapid decrease in CYP3A7 after birth, as well as a sharp increase
in CYP3A4 in the neonatal period to reach adult levels at one year of age (He et al., 2016).
3) Expression with onset occurring mostly in the third trimester with substantial increase in the
ﬁrst 1–2 years after birth. Isoforms include ADH1C, ADH1B, CYP1A1, 1A2, 2A 6, 2A7, 2B6, 2B7,
2C8, 2C9, 2F1, 3A4, FMO3, SULT2A1, UGTs, NAT-2 (Figure 4) (van den Anker et al., 2011).
In humans, total cytochrome P450 content in the fetal liver is between 30% and 60% of that found
in the adult and approaches adult values by 10 years of age (van den Anker et al., 2011). CYP1A1 is
expressed during early gestation, although expression of most of the other CYP enzymes occurs at or
near birth (CYP2B, CYP3A), immediately after birth and reaching adult levels within 30 days (CYP2E1)
or after the ﬁrst week after birth (e.g. CYP1A2, CYP2C). The CYP3A isoform is the most abundant CYP
in the human liver (> 50%) of all CYPs and gut and is responsible for the metabolism of more than
50% of known pharmaceuticals and xenobiotics. In terms of isoform, CYP3A7 activity is high
immediately after birth; during the ﬁrst days after birth, there is a shift from mainly CYP3A7 activity to
CYP3A4 activity (Lee et al., 2012). Further accounts of the ontogeny of phase I and phase II enzymes
are provided in recent reviews (van den Anker et al., 2011; de Wildt et al., 2014; O’Hara et al., 2015).
PB-PK models have been successful at predicting differences between neonates and adults for
CYP1A2 using caffeine and theophylline and CYP3A isoforms but poorer predictions were obtained for
CYP2D6 and CYP2C because of lack of model complexity or inadequate hepatic microsomal activity
data to fully describe the maturational process of functional enzymes (Alcorn and McNamara, 2002;
Ginsberg et al., 2004). Recently, several studies reported clearance values in neonates predicted using
in silico tools that incorporate in vitro enzyme PK parameters (maximum rate of metabolism (Vmax) and
Michaelis–Menten constant (Km)], in vivo clearance data from the literature in neonates and ontogenic
information of isoforms. In 70% of cases, the predicted median clearances in neonates were within
two-fold of the observed values (Johnson et al., 2006; Salem et al., 2014).
Figure 4: Schematic depiction of drug-metabolising enzyme ontogeny. The post-natal pattern is
expressed as percentage of the adult level. Abbreviations: CYP, cytochrome P450; TPMT,
thiopurine S-methyltransferase; UGT, UDP-glucuronosyltransferases; SULT, sulfotransferases;
FMO, ﬂavin-containing mono-oxygenase. Reproduced with permission (de Wildt et al., 2014)
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Finally, the extent of metabolism can be inﬂuenced by a number of factors including polymorphic
expression of enzymes and transporters (CYP2D6, CYP2C9, CYP2C19, OATP, P-Gp) and the ontogeny
of the rate of hepatic blood ﬂow (particularly relevant for compounds with a high hepatic ratio).
Immediately after birth, blood ﬂow through the liver rapidly changes with the ductus venosus closing.
In most cases, full closure will be within 1 week. With the ﬁrst feed, portal blood ﬂow increases
leading to a rapid increase in hepatic functions and induction of a number of enzyme groups. With
feeding bacterial colonisation of the gut begins, and varies with the type of feeding (i.e. breastfeeding
or formula). Several studies have noted that because of such acute changes standard pharmacological
models of hepatic extraction, metabolism and blood ﬂow are not applicable to neonates and that they
are relevant only once the ductus venosus is fully closed (van den Anker et al., 2011).
Excretion
Excretion is a key step in ADME processes being the ﬁnal removal of a xenobiotic and/or its
metabolites from the body mostly via the renal (i.e. urine) or hepatic routes (i.e. faeces). Renal
excretion is particularly important for drugs and xenobiotics that are excreted as parent compound
without metabolism and water-soluble metabolites if they possess toxicological properties (Mooij et al.,
2016). When dealing with renal excretion of chemicals, renal clearance can be several-fold lower in
neonates compared to older children and adults for lipophilic, hydrophilic, and organic ions (van den
Anker et al., 1995; Clewell et al., 2002). Creatinine is a standard marker of renal function that
becomes an accurate biomarker during the ﬁrst weeks of post-natal life (O’Hara et al., 2015).
PB-PK models in neonates and young infants for drugs and environmental chemicals that are
primarily cleared by the kidney have been developed using data for rates of glomerular ﬁltration,
tubular secretion, tubular reabsorption, and renal blood ﬂow (Alcorn and McNamara, 2002; Johnson
et al., 2006; DeWoskin and Thompson, 2008; Salem et al., 2014).
The maturation of the kidney, or nephrogenesis, is complete within 36 weeks of gestation followed
by post-natal changes in renal and intrarenal blood ﬂow. The glomerular ﬁltration rate (GFR) at birth is
approximately 2–4 mL/min per kg in term neonates (one third of the adult value expressed on the
basis of body surface area) and as low as 0.6–0.8 mL/min per kg in preterm neonates. During the ﬁrst
2 weeks of life, GFR increases rapidly to half of the adult value within 3 months and then follows a
steep rise to adult values within 8–12 months. Such an increase in GFR in the ﬁrst weeks of life is
mainly driven by an increase in renal blood ﬂow. Tubular secretion is around 25% of adult levels at
birth, and increases more slowly and more variably than GFR, not approaching adult levels until
1–5 years of age. Limited data on renal plasma ﬂow indicate neonatal rates of only 10–20% of adult
values that rapidly increase to 50% by 6 months, and then approach adult levels by 1–2 years of age
(Alcorn and McNamara, 2002; van den Anker et al., 2011).
Kidney maturation in the neonate also involves changes in the expression of a number of
transporter isoforms together with developmental changes in signal transduction affecting the capacity
of renal tubules to reabsorb water and solutes. However, beyond expression levels, little is known
about the ontogeny of human membrane transporters and its consequences on the PK of xenobiotics
(Brouwer et al., 2015; Gattineni and Baum, 2015).
The renal function reaches 50% of the activity of adults within the ﬁrst 2 months of age. A number
of analyses showed overall 1.5- to 3-fold differences between neonates, infants and healthy adults for
renal clearances and total clearances and half-lives of substances that are cleared by the kidney (e.g.
antibiotics) (Hattis et al., 2003; Dorne et al., 2005; Valcke and Krishnan, 2013) (Figure 5). For the oral
route, limited data showed that clearances were slightly higher in neonates and infants compared with
healthy adults and associated with larger variability. For renal excretion, it is considered that an
additional UF of 2–3 would cover the differences between adults and infants below the age of
16 weeks. However, so far, the analyses from the literature have been based on compounds that are
eliminated rapidly by the kidney and comparative elimination patterns between neonates, infants and
healthy adults and for persistent compounds are as yet unavailable.
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To illustrate the inﬂuence of immature renal function and immature enzyme activity, the example of
the kinetics of propylene glycol should be mentioned. Propylene glycol is both eliminated by
metabolism through alcohol dehydrogenase and by renal excretion. In adults, renal excretion accounts
for 45% of the clearance (De Cock et al., 2014). In a study by de Cock et al. (2013), infants with GA
between 24 and 41 weeks at birth, were investigated at an age between 1 and 82 days and a birth
weight between 630 and 3,980 g (De Cock et al., 2013). The mean clearance in this infant population
was 0.085 L/h whereas the clearance in adults is known from the literature to be 8.64–23.4 L/h per
1.73 m2 (Speth et al., 1987). The clearance of propylene glycol was dependent on post-natal age and
on body weight of the infants. This example also shows that this guidance cannot give general
recommendations for preterm newborns and that HBGVs for substances used in this age group require
special consideration.
Transporters
Membrane transporters can play an essential role in the transport of endogenous and exogenous
compounds, and mediate the uptake, distribution, and excretion of many drugs. Historically, such
transporters were not considered with phase I and phase II metabolism and, over the past two
decades, phase I and II metabolism has been extended to a concept of four phases, which now
includes phase 0, namely the cellular uptake of compounds, and phase III, the transport of
compounds out of the cells. Cellular transporters belong to two main clusters of transporter families:
the solute carrier (SLC) families and the adenosine triphosphate (ATP) binding cassette (ABC) carriers.
SLC transporters include the human organic anion transporting polypeptides (OATPs) and human
organic cation transporters (OCTs), and are often denominated as phase 0 uptake transporters. ABC
transporters are often called efﬂux pumps or phase III and include examples of importance such as
P-glycoproteins and multidrug resistance proteins (MRPs) (Hillgren et al., 2013; Doring and Petzinger,
2014; EFSA, 2014). Transporters are mostly expressed in liver, kidney, the adrenal gland and the lung
(Doring and Petzinger, 2014).
Examples of transporters of physiological importance in the kidney include the OATPs expressed in
the kidney that are involved in the ﬁnal excretion of phase II conjugates. OATPs have low activity at
birth then increase rapidly to high levels, higher than those seen in adults, over the ﬁrst few weeks of
life and then begin to decline to adult levels. Such a change in secretion is independent of the changes
in renal mass. Exposure to hormones and antibiotics, such as penicillin, also increases organic anion
transporter activity (Mooij et al., 2016).
Figure 5: Maturation of renal function in the infants and young children. The ﬁgure shows para-
aminohippuric acid clearance, reﬂecting the ontogeny of renal blood ﬂow, and glomerular
ﬁltration rate as a function of age. Please note the non-linearity of the scale for the X-axis.
Reproduced with permission (Kearns et al., 2003)
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Ontogeny of metabolic pathways and its impact on clearance
Ontogeny of metabolic pathways in neonates has been shown to be isoform-speciﬁc and the
quantiﬁcation of its impact on acute and chronic elimination of xenobiotics is an important aspect of
risk assessment (Hattis et al., 2003; Dorne et al., 2005; Valcke and Krishnan, 2013). If the enzymes
involved in the metabolism of the substance are known, the expression level of the enzymes can be
taken into consideration. For example, newborns need only 25% of the dose of a one-year-old infant
to get the same plasma concentration of morphine, which is metabolised by UGT2B7 and other UGT
isoforms (Knibbe et al., 2009; Sato et al., 2012).
If the enzymes involved in the metabolism of a substance are not known, it should be assumed
that the activity levels of the enzymes are lower compared to adults. Consequently, the clearance of
substances may be lower compared with the adult population. Since the clearance is the product of
the elimination constant (ln 2/half-life) and the volume of distribution, both age-dependent in infants,
half-life and clearance are not linearly related. The pattern is illustrated in Figure 6 from Valcke and
Krishan (2013) based on the data of (Ginsberg et al., 2002) and (Hattis et al., 2003).
Other studies have given more detailed information, indicating the relative activity of speciﬁed
enzymes in children of different ages versus the adult (Table 6).
It should be noted that in contrast to other conjugation enzymes, sulfotransferases are expressed
at the same level in infants as in young adults as indicated by semi-quantitative Western blot analyses
of liver samples (Duanmu et al., 2006).
Figure 6: Half-life and clearance ratios (child/adult) as a factor of age. Reproduced with permission
Valcke and Krishnan (2013)
Table 6: Estimates of age-dependent enzyme activity as ratio child/adult
Age
Enzyme activity (ratio child/adult)
CYP 3A4 CYP 1A2 CYP 2E1 UGT 2B7 UGT 1A6
Premature 0.1 0.02 0.1 0.015 0.015
Term 0.2 0.05 0.21 0.05 0.1
7 days 0.24 0.1 0.32 0.06 0.11
1 month 0.5 0.2 2.5 0.1 0.16
3 months 0.7 0.25 0.45 0.3 0.25
6 months 1.1 0.29 0.45 0.7 0.36
1 year 1.25 (1–3 years) 0.34 1.0 1.0 0.5
10 years 1 1 (8 years) 1 1 1
Modiﬁed from (Edginton et al., 2006). Values similar to those given by Edginton et al. (2006) have also been reported in other
studies (Cresteil et al., 1985; de Wildt, 2011; Saghir et al., 2012).
CYP: cytochrome P 450; UGT: uridine diphosphate glucuronosyltransferase.
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As a generalisation, if the substance is mainly metabolised, the reduced metabolic activity of most
of the enzymes will lead to higher concentration in plasma. If the toxicity is owing to the parent
compound, the substance may have a higher toxicity owing to the higher internal exposure. A more
complex situation is present if the toxicity is due to bioactivation of the parent compound. The
resulting toxicity depends on the potential presence of parallel metabolic pathways with a more
advanced development leading to non-toxic metabolites by which the parent compound will then
mainly be eliminated and/or on the maturity of the kidneys, which may excrete the parent compound
and the formed metabolites being toxic or non-toxic.
If the enzymes involved in the metabolism are not known, the general approach by Valcke and
Krishnan (2013) can be applied. The study provided half-life and clearances for different age groups as
the ratio child to adult based on the data of Ginsberg et al. (2002) and Hattis et al. (2003) that
analysed kinetic studies, mainly of drugs, in the different age groups. The data given in Figure 6
(Valcke and Krishnan, 2013) are the means of the ratios from all the kinetic studies. If the metabolic
pathway and the involved enzymes of a substance are known, available detailed information could be
used to adjust for enzyme activity in the speciﬁc age group. The activity of several CYP-enzymes and
of other enzyme can be taken from Table 6, which is based on a publication by Edginton et al. (2006).
5.2.4. Summary
Absorption of substances in general might be slower in infants below 16 weeks of age than in older
ones, but the amount absorbed is not dependent on the age. Once absorbed and systemically
available, the distribution of the substance may be different from that in adults owing to the age-
dependent changing of body composition (neonates: larger extracellular and total-body water spaces
and lower fat content). Other factors to be considered are the differences in regional blood ﬂow, organ
perfusion and cardiac output between infants and adults. In addition, the total plasma protein binding
capacity (especially albumin) is lower in infants.
Infants show a unique pattern of development for individual enzyme isoforms involved in phases I
and II metabolism, with a reduced capacity at birth. However, owing to overlapping substrate
speciﬁcities, the overall impact on the clearance and half-life of substances (decrease in clearance,
increase in half-life) is limited, being generally up to two- (full-term) to threefold (preterm) lower when
comparing infants with healthy adults. Likewise, renal function is also reduced at birth and its function
increases in the ﬁrst year of life. Therefore, if the precise metabolic pathway is not known and it is not
known to which extent the substance is excreted by metabolic elimination or by renal excretion, an
additional UF of 3 could be considered as a conservative option to account for the reduced elimination/
excretion. When the precise metabolic pathway for a given substance is known, the age-speciﬁc ratio
child/adult (Table 6) can be used. In rare instances where the data are available for the metabolic
clearance for this age group, then chemical-speciﬁc UFs can be used. Special considerations may need
to be taken into account if a substance is metabolised through a pathway that is polymorphic, such as
for CYP2D6 substrates. The importance of the polymorphic expression of, for example, CYP2D6
depends on the relative contribution of this metabolic pathway to the overall elimination. A case-
by-case approach is advisable to account for a potential higher susceptibility of poor metabolisers in all
age groups.
Speciﬁc situations may exist that will affect the impact of the immaturity of the infants ADME
system on the magnitude of the difference in internal dose between infants below 16 weeks of age
and adults and the potential toxicological consequences. For example, extremely and very preterm
neonates represent a special subpopulation under medical supervision that would not be sufﬁciently
protected by the additional UF of 3 due to the considerable immaturity of the ADME system, and
would necessitate a case-by-case approach.
For compounds for which effects are dependent on long-term body burden (e.g. cadmium, dioxins),
the impact of immaturity of metabolism and excretion is likely to be minimal.
5.3. The developing brain and brain barriers
When describing the development of the central nervous system (CNS), the differential role
between the developing brain barriers (BBs) and the developing neuronal and glial cells needed
considering. In the context of chemical risk assessment, a key impact of the BB is on the accessibility
of compounds to their target neuronal and glial cells, and as such, the BB can be regarded as a major
toxicokinetic modulator for the distribution of chemicals and other substances. The BB inﬂuences the
distribution to the target cells and hence the concentration at the site of action, whereas the ability of
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a chemical to induce adverse effects on neuronal or glial cells reﬂects the toxicodynamic properties of
the compound.
5.3.1. The developing brain barriers
Once a potential neurotoxin has entered the systemic circulation, it will reach the CNS via cerebral
blood vessels. The blood–brain barrier (BBB) is formed by endothelial cells, which, in contrast to other
endothelial cells, have continuous intercellular tight junctions, lack fenestrations and undergo
extremely low rates of transcytosis. Astrocytes, pericytes and extracellular matrix components
contribute structurally and functionally to the BBB (Obermeier et al., 2013). However, the brain and
spinal cord are bathed in ﬂuid that is chemically different from the blood (Saunders et al., 2014). In a
risk assessment, it is therefore desirable to understand the BBs and how they control access of
substances, to the neuronal cells of the CNS at all stages of development.
Development of the BBB commences as the neural tube forms and mesenchymal cells surround
and penetrate developing neuroectoderm. Because the brain grows and new blood vessels form
throughout gestation and well into the post-natal period, the barrier is continually forming fresh new
areas and expanding. The barrier is probably functional from very early in the development of the CNS
(Saunders et al., 2014). The key component of the BBB is a continuous vascular endothelium
controlling bidirectional transport of large and small molecules through regulation of transcellular and
intercellular pathways between circulating blood and the neuronal compartment.
The observation of unconjugated bilirubin penetration to deep human brain structures in the
condition of neonatal kernicterus was previously taken incorrectly as evidence for the BBB being leaky
in the period shortly after birth (Goldmann, 1913; Gr€ontoft, 1954; Kumar et al., 2010). However, it is
now generally accepted, based on considerable experimental evidence from vital dye and radioactive
tracer experiments, that this is not correct and that the barrier in the fetus and newborn should be
described as ‘immature’ and not as ‘leaky’ (Saunders et al., 2014).
Extent of the BBBs
There are several (albeit some relatively minor) routes that allow access to the CNS and brain that
lie parallel to the BBB. One is the route to the hindbrain vomiting centre where substances derived
from blood gain direct CNS access allowing them to create part of a neurochemical reﬂex that is
protective against ingested poisons.
In dye injection studies in humans and animals, performed within hours of birth, the brain was
generally unstained although dye did stain smaller speciﬁc parts including the choroid plexus and the
circumventricular organs, which lie just outside the BBB. The substantially higher concentration of
protein in cerebrospinal (CSF) observed at the time of maximum growth of the brain is caused by
speciﬁc transport from the blood to the CSF across the choroid plexus epithelium. Therefore, this
region has been called the blood–CSF barrier (Adinolﬁ et al., 1976; Adinolﬁ, 1985; Liddelow et al.,
2011a, 2011b, 2013). A blood–retinal barrier is also considered as a distinct interface, as are the roof
of the third and fourth ventricles, capillaries in the pineal gland, the roof of the diencephalon and the
pituitary gland where there is release of endocrine secretions directly into the blood stream.
Uncertainty stems from the fact that study of transport at several of these sites has not been
extensive.
Permeability and transport of substances across the BBB
Substances can gain access to the glial and neuronal cells by simple passive diffusion across the
BBB (which physicochemically can be regarded as an interrupted phospholipid membrane) or by
facilitated diffusion or by active transport, depending on their physicochemical properties. Lipophilic
substances will cross the BBB by passive diffusion, whereas, as in the case of water-soluble
compounds, speciﬁc membrane transport proteins play a major role for their transport across the BBB
and in and out of the cells (Obermeier et al., 2013). Small molecules such as amino acids and glucose
are transmitted across endothelial cell plasma membranes by transporters, carriers and channels. Brain
endothelia exhibit ion channels affecting Ca2+ ﬂux and vasoactive secretion of nitric oxide, histamine,
substance P, endothelin-1, bradykinin also prostacyclin, haemostatic factors such as tPA and von
Willebrand factor (Ennis et al., 1996; Kimelberg, 2004). Macromolecules appear to use clathrin
(cationic preference) and caveolin (anionic preference). These coated endocytic and transcytotic
pathways may lead to lysosomal degradation of their contents or may carry their contents intact
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across the endothelium (Narushima et al., 1999; Lossinsky and Shivers, 2004). Transport across the
BBB can be paracellular through the intercellular space between the cells or transcellular.
Paracellular transport across the BBB is by passive or facilitated diffusion alone. It is based on
electrochemical, hydrostatic and osmotic gradients, characterised by higher conductance and lower
selectivity, has similar conductance and selectivity in either apical-to-basal or basal-to-apical directions
and has well deﬁned values of electrical conductance, as well as charge and size selectivity.
Evidence that endothelial gene expression patterns differ in development, observed higher rates of
synthesis of certain proteins at early time points and differential expression of membrane transporter
proteins can account for the majority of the differences in solute composition of the CNS interstitial
ﬂuid and blood (Daneman et al., 2010). This is consistent with evidence that even early simple
endothelial cell sinusoid forming arrays form a ‘tight enough’ layer to restrict passage of polar
molecules as small as sucrose (Saunders et al., 2014). Nevertheless, there is uncertainty in predicting
the handling of particular substances where their transport has not been speciﬁcally studied.
BBB enzymes such as ɣ-glutamyl transferase, alkaline phosphatase and aromatic decarboxylase are
enriched in cerebral microvessels compared with similar sized vessels elsewhere in the body. They
metabolise neuroactive compounds in blood and may be differentially expressed in apical and basal
domains (Betz and Goldstein, 1978; Betz et al., 1980).
Altered permeability of the barrier
The BBB usually constitutes an effective barrier to infection and within it is regarded as an
immunologically privileged site (Muldoon et al., 2013). Many pathological effects, infectious agents and
physiological factors may disrupt BBB function leading to neurotoxicity, encephalitis, meningitis and
brain oedema. Some of these have increased incidence in the newborn (Lee et al., 1997; Kimelberg,
2004). Disruption of paracellular pathways (Chen et al., 2003) may be more serious than, for example,
pneumolysin effects on transcellular pathways (Nizet et al., 1997). Toxins, viral infections, eukaryotic
parasites and fungi penetrate the BBB, rendering it permeable to other agents (Stamatovic et al.,
2008). Inﬂammatory mediators, matrix metalloproteinases, growth factors prostaglandins reactive
oxygen and nitrogen affect the function of the BBB (Stamatovic et al., 2008).
It is not totally understood how all the ‘opening mechanisms’ operate but opening by any means
will affect local toxicokinetics and increase CNS exposure to neurotoxins. Some appear to affect only
the paracellular route possibly through interleukin 1-b and CXCL8, whereas compounds such as TNF-a
increase only transcellular permeability (Butt et al., 1990). Sometimes opening is transient such as
when histamine causes intracellular Ca2+ accumulation. Thrombin is one rather potent cause of
cytoskeletal reorganisation that results in more prolonged opening of the BBB (van Hinsbergh and
Amerongen, 2002). This pathway incidentally indicates a theoretical biologically plausible mechanism of
damage to the BBB from birth trauma. Highly effective inducers of BBB hyperpermeability other than
thrombin (Lee et al., 1997) are amyloid-b peptide (Mackic et al., 1998) and intracellular Ca2+ (Brown
et al., 2004). Leukocytes in blood may cause BBB permeability and use diapedesis to enter the brain
themselves (Alvarez and Teale, 2006). Exogenous pharmacological agents such as nicotine are known
to affect the BBB and neonicotinoid pesticides may through their action on intracellular Ca2+ also
disrupt BBB function. In vitro models of the BBB are in development, although no model validated for
risk assessment is currently available (Dehouck et al., 1990; Garberg et al., 2005; Culot et al., 2008;
Paolinelli et al., 2013).
5.3.2. The developing brain
The development of the human brain starts on day 19 in the human embryo and comprises a
number of key stages that progress through the neonatal and infant period well into adolescence
before the brain is fully mature (European Medicines Agency, 2009). These steps consist of neuronal
proliferation, migration, organisation and myelination. In a ﬁrst phase, neuronal proliferation and the
generation of radial glia occur between gestation weeks 8 and 16, followed by a second phase
between 5 months and 1 year of life, consisting of glial multiplication (while neurogenesis and
neuroproliferation are continuing). Post-natal brain growth in humans is prolonged and proceeds at
fetal growth rates for nearly a year or even longer (Neubauer and Hublin, 2012). As previously
reviewed by (EFSA PRR Panel, 2013; ten Donkelaar and Lammens, 2009), the development of the
cerebellum is protracted. It commences early in the embryonic period. The development occurs in two
waves in humans, the adult number of narrow, leaﬂike gyri of the cerebellar cortex (referred to as folia
or cerebellar laminae) is achieved by around 2 months post-natally and the extragranular layer ﬁnally
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disappears around the seventh month post-natally. Sensitivity of the cerebellum to neurotoxins in the
under 16 week period when it is developing is therefore potentially greater than in older infants and
adults.
Neurotransmitters, such as glutamate, c-aminobutyric acid, dopamine, serotonin, acetylcholine,
opiates and adenosine, play a crucial role in the control and modulation of pre- and post-natal brain
maturation. For instance, neurons with c-aminobutyric acid are involved in migrational events following
radial glial guides whereas N-methyl-D-aspartate receptors transduce excitatory signals in the
developing brain, inﬂuence synaptic construction, and promote proliferation and migration of neuronal
progenitors. The latter events play a crucial role in the development of brain plasticity, which results
from a subtle balance between neuronal proliferation and physiological apoptosis.
The vulnerability of the immature brain derives from incomplete myelination and receptor-
maturation as well as a lack of endogenous protectors especially in the preterm neonate. This
vulnerability can be exacerbated by pre- and post-natal events, including maternal diseases and
infections that affect brain maturation.
Increased intracerebral bilirubin concentrations may lead to bilirubin encephalopathy and severe
brain damage (kernicterus). The pathogenesis of bilirubin encephalopathy is multifactorial and involves
an interaction between unconjugated and free bilirubin levels, albumin binding capacity, acid–base
status and neuronal susceptibility to injury (Watchko, 2016).
5.3.3. Summary
The developing BBB is similar to the adult BBB, in that it possesses functional tight junctions and
inﬂux and efﬂux transporters. Hence, contrary to previous assumptions, the healthy BBB in the ﬁrst
16 weeks, although immature, is considered functional and not leaky. However, the expression/activity
of transporters and metabolising enzymes appears to vary from adult patterns to meet the needs of
the developing brain and apparently give rise to the measured differences in uptake (Ek et al., 2012)
and metabolism rates (e.g. CYP2D6) across the neonatal and infant BBB (Mann et al., 2016). The
movement of molecules across the BBBs depends on their physicochemical properties, the local
physiological milieu (e.g. pH) and the need for transporters (i.e. inﬂux and efﬂux transporters) and
their ontogeny, activity and speciﬁc location. The differences may result in greater vulnerability to
chemicals than in the adult (Johansson et al., 2008; Ek et al., 2012; Neal-Kluever et al., 2014).
Uncertainty in predicting speciﬁc exposure of the CNS to chemicals derives from knowledge gaps
concerning the degree to which alternative pathway barriers such as the blood choroid plexus barrier
are functional, precise differentiation state of the BBB.
5.4. The developing immune system
The immune system is a defence system designed to react to exposure to any foreign and ‘non
self’ component. To this aim, a large number of cells and humoral mediators interplay and contribute
to an adequate immune response, both by non-speciﬁc (innate)- and antigen-speciﬁc acquired (or
adaptive) immune responses (Delves et al., 2017). In the course of these responses, efﬁcient
mediators are released and potent mechanisms are triggered that need to be adequately regulated to
avoid any undesirable injury to the responding organism itself, including auto immunity and/or allergy
(Delves et al., 2017). Finally, it must be considered that the immune system includes both systemic
and local (e.g. lungs, skin, gastrointestinal tract) mechanisms, which may react independently but
remain interacting. In this regard, in the neonate the development of the gastrointestinal immune
system may be especially vulnerable and deserves a speciﬁc attention (Brugman et al., 2015).
At birth, the immune system is far from being completely functional and requires some time before
being fully efﬁcient. Newborns mostly rely on their innate (non-speciﬁc) immune system as their
adaptive (speciﬁc) immunity and their mainly Th2 skewed adaptive (speciﬁc) immunity fully develop
only later in life, as result of a delayed onset of the Th1 immunity and neonatal antibody responses.
The imbalance between Th1 and Th2 responsiveness in the newborn is assumed to contribute to the
susceptibility of infants to infection and allergic reactions (Dietert and Piepenbrink, 2006; Siegrist and
Aspinall, 2009; Zaghouani et al., 2009; Krishnamoorthy et al., 2012). The development and maturation
of the immune system, are initiated in utero during the fetal period, and expand in time through the
ﬁrst years of childhood (Pettengill et al., 2014). Accordingly, adequate building up of this system is
especially prone to any factor disrupting the numerous mechanisms involved in these processes during
the fetal life, in the neonate and the young infant (Gasparoni et al., 2003; Kotiranta-Ainamo et al.,
2004; Hartel et al., 2005; Dietert and Piepenbrink, 2006; Velilla et al., 2006; Adkins, 2007; Morein
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et al., 2007; Greer et al., 2008; Saito et al., 2008; Belderbos et al., 2009; Dietert, 2009b; Walker et al.,
2011; Renz et al., 2012; Sharma et al., 2012; Ygberg and Nilsson, 2012; Neal-Kluever et al., 2014;
Valiathan et al., 2016).
In addition, it should be considered that the immune system shares mediators, and therefore
interferes with, for example, the endocrine and the nervous systems (Madhusudan et al., 2013;
Kabouridis and Pachnis, 2015); consequently, any alteration of one of these mediators may inﬂuence
the development of any of the systems that share these mediators.
Environmental inﬂuences
From a risk assessment standpoint, the issue at hand is whether exposure to immunotoxicants
during development and maturation of the immune system produces more severe or persistent health
aspects than similar exposure after the immune system is fully mature. It has been reported that adult
exposure assessment does not always predict the risk of perinatal immunotoxicity (Dietert, 2009a,
2011; DeWitt et al., 2012; Kollmann et al., 2012; Krishnamoorthy et al., 2012).
Although not established absolutely, it is generally recognised that the immature immune system is
more or at least differently (qualitatively) susceptible to immunotoxicants than the fully mature system
(Hrubee et al., 2005; DeWitt et al., 2012; Kollmann et al., 2012; Krishnamoorthy et al., 2012). Several
studies using animal models have shown that the developing immune system is altered by (immuno)
toxicants, such as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), tributyltin or Pb, at doses that were
signiﬁcantly lower than those required to produce effects in the adult. In addition, different effects can
be observed depending on the age at which the organism is exposed. For example, tributyltin affects a
broader spectrum of immune function upon perinatal than adult exposure, and perinatal TCDD
exposure mainly affects cell-mediated immunity (decreased, with males more sensitive than females),
whereas adult exposure especially affects humoral immunity (enhanced) (Luebke et al., 2006).
Furthermore, sequels of exposure to immune toxicants during development may be particularly
persistent in contrast to effects observed following adult exposure, which generally occur at higher
doses (Holladay and Smialowicz, 2000).
Maternal inﬂuences
Being fed with breast milk in the ﬁrst weeks of its life is for the newborn a signiﬁcant opportunity
for an efﬁcient and harmonious development and function of its immune system (Marques et al., 2013;
Yong et al., 2013). For example, breastfeeding provides the newborn with immunoglobulins and other
components or modulators (e.g. fatty acids, oligosaccharides) of the immune system. However,
composition of the breast milk can be altered by contamination with substances that may be present
in the foods eaten by the mother and that are able to cross from the blood to the milk, and this may
result in disturbance of the beneﬁcial properties of breast feeding.
In addition to direct beneﬁcial effects on the immune system itself, breast milk favours an adequate
colonisation of the gastrointestinal tract with a microﬂora that helps in the maturation of the immune
system (Parigi et al., 2015). The human gut microbiota, the mixed-species community of microbes that
reside in the gastrointestinal tract, plays a critical role in physiological and immunological maturation
and homoeostasis (Donovan et al., 2012). Epidemiological studies suggest that the common feature of
many allergy risk-related exposures is their inﬂuence on the founding and early development of a
child’s gut. Perturbations to gut bacterial community composition during the neonatal period have
been associated with a variety of paediatric disorders, highlighting the relationship between early life
gut microbiota development and childhood health status. Microbial exposures could alter the risk of
subsequent allergic disease and asthma. The human microbiome plays a role in immune regulation,
which may impact against the development of allergic diseases (Bengmark, 2013; Alegre et al., 2014;
Kabat et al., 2014; Salzman, 2014). In this context, it should be noted that the uterus may also play
an indirect role in the immune development through fetal microbial colonisation (Brugman et al., 2015;
Romano-Keeler and Weitkamp, 2015).
Allergic reactions
Data on the consequences of exposure to an allergen in infancy are available mainly from studies
investigating food allergy prevention involving older infants from the age of 4 months onwards.
The concepts of an ‘optimal window’ for oral introduction of allergens during which the chance for
the development of immune tolerance is greatest, have recently been discussed (Gray, 2015). They
were based on studies focussing on the timing of introduction of allergenic food components, which
led to a ‘paradigm shift’ of strategies, away from the earlier concept of ‘strict, total allergen avoidance’,
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towards a concept of ‘tolerance induction’ by early oral introduction of allergenic foods (de Silva et al.,
2014; Tey et al., 2014; Gray, 2015; Perkin et al., 2016). These studies, even if they were not without
methodological ﬂaws, suggested that early introduction of allergens (e.g. from egg, wheat or milk),
between 4 and 6 months or below 7 months, respectively, may protect against allergies (Poole et al.,
2006; Katz et al., 2010; Koplin et al., 2010; Nwaru et al., 2010). Similarly, a randomised control trial on
optimal timing of peanut introduction in the infant at risk of peanut allergy (Du Toit et al., 2015)
showed that early introduction of peanut signiﬁcantly decreased the development of peanut allergy
amongst children tested negative on a peanut skin prick test and those at high risk for this allergy and
modulated the immune response to peanuts. Other studies showed that feeding of hydrolysed or
partially hydrolysed cow’s milk-formulae led to reduced allergic manifestations and food sensitisations
compared to standard cow’s milk-based formulae (Muraro et al., 2014; von Berg et al., 2016).
As is reﬂected by current recommendations supported by the European Academy of Allergy and
Clinical Immunology (Muraro et al., 2014), existing information reports that infants at high risk may
beneﬁt from reduced exposure to substances being potential allergens in the ﬁrst 4 months of their
lives (Halken, 2004; Poole et al., 2006; Katz et al., 2010; Koplin et al., 2010; Nwaru et al., 2010; Du
Toit et al., 2015).
5.4.1. Summary
The developing immune system in fetal and early post-natal life is particularly sensitive and
exposure to immunotoxicants may result in persistent effects on the immune system that last or
appear only long after exposure and in general, may also occur at lower doses than during adult
exposure. In addition, immune effects seen upon perinatal or adult exposure may be different. A
number of compounds or types of exposure may produce different ranges or severities of outcomes
depending on the time of exposure during the immune system development. Different and
unpredictable arrays of alterations (quantitative and qualitative) may be expected when the exposure
occurs in utero or in the early neonate versus adult exposure. They may be associated with chronic
immunological conditions such as autoimmunity, immune deﬁciency, inﬂammation and allergic
reactions. Altogether, neonates have speciﬁc features in the development and maturation of their
immune system, which make their response to an immunogenic/allergenic compound different from
that of an adult and therefore, deserve speciﬁc studies.
5.5. Development of the reproductive system
Adequate measurements of reproductive function and development include endpoints early in life
such as development of sex organs and attainment of pubertal milestones. The reproductive system is
heavily inﬂuenced by the endocrine system, which facilitates the release of hormones that inﬂuence
growth and development of many organ systems (Neal-Kluever et al., 2014).
Reproductive organs develop in utero and are immature at birth (Lemasters et al., 2000). Some of
the critical steps in the formation of the reproductive system take place during embryogenesis. Sexual
maturation and related events do not occur until puberty.
5.5.1. Female reproductive organ development
At birth, female infants possess their entire complement of oocytes and further oogenesis does not
occur (Neal-Kluever et al., 2014). There are many milestones to accomplish for female reproduction
such as maturation of reproductive tissues, steroid hormone production, development of external
genitalia, development of sexual behaviour and cyclic hormonal signalling events (Beckman and
Feuston, 2003). The period of birth through 6 months is relatively quiescent in terms of female
reproductive development, although chemical exposures during this period might have latent effects
not detectable until reproductive maturation. For example, girls perinatally (in utero and via
breastfeeding) exposed to high levels of polybrominated biphenyl, as a result of an accidental
contamination with a ﬁre retardant in Michigan in 1973, had an earlier age at menarche compared to
breastfed girls exposed to lower levels in utero or girls who were not breastfed (Blanck et al., 2000).
5.5.2. Male reproductive organ development
The ﬁrst 6 months after birth are considered a sensitive developmental window for the testes
(Lemasters et al., 2000). The early post-natal testis exhibits a high proportion of immature Sertoli cells
(Mendis-Handagama and Ariyaratne, 2001) that proliferate from birth until 6 months of age when the
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adult number of Sertoli cells is achieved (Lemasters et al., 2000). The number of Sertoli cells that
develop during this period directly inﬂuence the number of spermatogonial cells that can be supported
(Cortes et al., 1987), and hence this heavily affects sperm count and fertility later in life (Lemasters
et al., 2000). Furthermore, the infant testes have a higher susceptibility for toxic injury compared to
the adult because the blood–testis barrier does not fully develop until puberty (Camatini et al., 1981).
There is one major androgen surge during human male development, namely from 4 to 6 weeks of
gestation, followed by a secondary surge shortly after birth. Leydig cells undergo a rapid period of
growth around the third or fourth month after birth (Codesal et al., 1990; Mendis-Handagama and
Ariyaratne, 2001), which is related to a transient increase in activity of the hypothalamic–pituitary–
gonadal (HPG) axis (Mann and Fraser, 1996; Prince, 2001).
5.5.3. Summary
The development of the female reproductive system in infants below 16 weeks of age is relatively
quiescent. For the development of the male reproductive organ the testis; however, this is a sensitive
period. The early postnatal testis exhibits a high proportion of immature Sertoli cells (Mendis-
Handagama and Ariyaratne, 2001), which proliferate from birth until 6 months of age when the adult
number of Sertoli cells is achieved (Lemasters et al., 2000). Effects on the functional development of
reproductive organs generally become apparent later in life.
5.6. Development of the endocrine system
5.6.1. The hypothalamic–pituitary–gonadal (HPG) axis
In humans, the HPG axis develops in utero by the end of the ﬁrst trimester (Mann and Fraser,
1996; Grumbach, 2002). Thus, the components of the HPG axis are present at birth. In the ﬁrst 6
months after birth, there are transient increases in follicle-stimulating hormone (females) and
luteinising hormone (males), followed by a period of diminished activity that lasts until puberty
(Grumbach, 2002). There are some indications from observational studies that the HPG axis may be
disrupted by chemicals that result in altered puberty (Blanck et al., 2000; Ouyang et al., 2005; Den
Hond and Schoeters, 2006; Louis et al., 2008; Korrick et al., 2011; Maranghi and Mantovani, 2012;
Deodati et al., 2016). Although changes in the onset of puberty have been associated with exposure to
several chemicals, the underlying mechanism remains unknown.
Minipuberty is the name given to the activation of the HPG axis. It is described in detail and
summarised here because it coincides with the period of concern for this risk assessment (Kuiri-
H€anninen et al., 2014). From midgestation, the HPG axis is active. Near to term, placental hormones
cause its activity to be suppressed. Once the umbilical cord is cut at birth, the placental hormones no
longer reach the early infant’s body, and reactivation of the HPG axis increases circulating
gonadotrophin levels. Gonadotropin levels are still high during the ﬁrst 3 months of life but decrease
towards the age of 6 months (exceptionally follicle-stimulating hormone levels in girls remain high until
3–4 years). After this, the HPG axis remains inactive until puberty. The early post-natal availability of
gonadotropins mediates gonadal development. Male babies show testosterone levels peaking at 1–
3 months of age then declining following luteinising hormone levels, and this is important for proper
development of male genitalia. High gonadotropin levels in female babies promote maturation of
ovarian follicles and raised oestradiol levels.
Minipuberty is an under-researched area and knowledge of the mechanisms that suppress the HPG
axis until puberty is limited. Such data gaps contribute to uncertainty in risk assessment. However, it is
clear that the ﬁrst post-natal months of life provide targets for endocrine active substances (EFSA
Scientiﬁc Committee, 2013) that may have different endocrine mediated outcomes from those later in
development and in adulthood.
5.6.2. The fetal and infant adrenal glands
Development of the adrenal glands starts by day 25 of gestation. The fetal adrenal glands function
in cooperation with the placenta. By the fourth month of gestation, they are four times the size of the
kidney but, by birth, following a rapid decline of the fetal adrenal cortex, they are only one-third
the size of the kidney. Through apoptosis, the fetal adrenal cortex disappears almost completely by the
end of the ﬁrst year. At 1 year, a healthy human adrenal gland weighs approximately 1 g, but then
increases to a ﬁnal weight of 4–5 g when it is fully developed at 4–5 years (Ishimoto and Jaffe, 2011).
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These rapid changes from the fetal to the ﬁnal form of the adrenal cortex occur in the time window of
interest for this risk assessment. Premature babies, stillborn and some neonates that have experienced
intrauterine stress have microscopic cystic changes in adrenal glands an observation that adds
uncertainty to the risk assessment of substances found in food intended for preterm and term infants.
5.6.3. Adrenarchy and the hypothalamic–pituitary–adrenal (HPA) axis
As indicated above, effects at any early developmental stage may be reﬂected in deﬁcits at later
time points. At adrenarchy, the preparation for puberty, there is an increase in adrenal androgen
production by the zona fasciculata of the adrenal gland. This is biochemically detectable as a rise in
dehydroepiandrosterone sulfate (DHEA-S) commencing at approximately 6 years of age in both sexes.
It is a response to adrenocorticotropic hormone that causes a greater rise of 17-hydroxypregnenolone
and DHEA than the simultaneous rise of cortisol. The unique pattern of steroidogenic enzymes that
accompanies these changes includes expression of sulfotransferase 2A1 (a catalyst of the formation of
DHEA-S), which is the major adrenarchal steroid.
The onset of puberty varies across populations and sexes and is inﬂuenced by nutritional status.
Breast budding is normal in Afro-American and Mexican girls as early as 7 years (Rosenﬁeld et al.,
2009) but good data for the onset of male puberty is still unavailable (Bordini and Rosenﬁeld, 2011).
Premature or precocious puberty is deﬁned as onset 2 to 2.5 standard deviations earlier than
population norms. Precocious puberty is attributable to androgen and/or oestrogen effects. These may
be centrally mediated through the HPG axis, or in ‘peripheral’ precocious puberty from an autonomous
peripheral origin such as the adrenal glands, gonads, germline or neural crest derived tumours. It may
also have an exogenous basis. In boys with precocious puberty, where both testes are enlarged this
may be in response to luteinising hormone. This condition is HPG related or ‘central’ precocious
puberty. It could also be the result of a human chorionic gonadotropin-secreting tumour. Where both
testes are pre-pubertal in size, the most likely source of the androgens is adrenal. The exogenous
causes include topical exposure to lavender and tea-tree oil. Here, the effects are assumed to depend
on the anti-androgenic effects of these compounds which caused gynaecomastia in pre-pubertal boys
(Henley et al., 2007). Similarly, oestradiol in an Evamist spray, a menopausal symptom relief
prescription treatment, may cause precocious puberty in girls, gynaecomastia in boys and may affect
mammary glands in companion animals when inadvertent skin contact is made.11
5.6.4. The fetal and infant thyroid and parathyroid glands
The serum half-life of T4 is approximately 7–10 days in adults (Sabatino and Chopra, 1999), but is
approximately 3 days in neonates (Lewander et al., 1989; van den Hove et al., 1999). Thus, the T4
secretion from the thyroid gland has to be considerably higher in early life both to maintain steady-
state levels and to satisfy the requirements of the growing/developing newborn.
Moreover, the adult thyroid gland stores a large quantity of thyroid hormone in the form of
thyroglobulin, which is sufﬁcient to maintain normal levels of circulating hormone for several months
(Greer et al., 2002). By contrast, the neonatal gland stores very little T4; the amount stored has been
estimated at less than that required for a single day (van den Hove et al., 1999; Savin et al., 2003).
These differences indicate that the functional reserve available to adults is virtually absent in neonates;
consequently, any reduction in thyroid hormone synthesis in the neonate might result in a reduction in
circulating levels leading to hormone insufﬁciency.
The thyroid has a key role in many developmental processes. For example, in skeletogenesis,
thyroid hormone receptors (TRa1 and TRb1) are functional in growth plate hyaline cartilage cells,
osteoblasts and bone marrow stromal cells. T3 binds to TRa1 and regulates endochondral ossiﬁcation
through signalling pathways such as the Indian hedgehog/parathyroid hormone related peptide
feedback loop and the growth hormone insulin-like growth factor 1 and ﬁbroblast growth factor
receptor pathways (Braverman and Cooper, 2012). These processes are initiated as different
ossiﬁcation centres become active and continue until growth plate closure is complete. The process of
ossiﬁcation is extended: as examples, six ossiﬁcation centres that appear during gestation and the
neonatal period can be considered. They develop in the order calcaneum, talus, distal femur, cuboid
bone and proximal humerus. The ﬁrst of these appear at week 21 and all six are usually present by
weeks 41–42 (Pryse-Davies et al., 1974). The time of ossiﬁcation is a major difference between the
early infant and premature baby and an adult and allows for differences in response to toxicants.
11 Http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm220185.htm
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Interindividual variation in the timing of the onset of ossiﬁcation does add uncertainty to deﬁning
windows of temporal sensitivity to development of different parts of the skeleton as there is a wide
range of times of their ﬁrst appearance. Retardation and advancement are both correlated with other
factors. Retardation is associated with male sex, small-for dates babies, some congenital
malformations, multiple births, increasing maternal age and increasing parity. The thyroid plays also a
key role in neurological development, metabolism regulation, bone remodelling and other essential
functions (Boas et al., 2012). Disruptions in thyroid signalling can have widespread effects on infant
development (Zimmermann, 2011).
The structure and development of the parathyroid glands, of which four are usually found in
humans and most mammals, are well described in a recent publication (Kalinin et al., 2013). The
glands develop prenatally and are essential for skeletal growth during early post-natal development.
Parathyroid hormone (parathormone) is a peptide that controls the blood levels of calcium and
phosphate and hence also bone physiology. Its effects are antagonistic to those of thyroid derived
calcitonin, which downregulates osteoclasts and is most active during lactation and pregnancy
preventing excessive bone demineralisation. Parathyroid hormone increases gastrointestinal calcium
absorption by activating vitamin D, and promotes calcium conservation (reabsorption) by the kidney. It
is also a major regulator of serum phosphate concentrations by the kidney. It is an inhibitor of
proximal tubular reabsorption of phosphorus. Through activation of vitamin D the absorption of
phosphate is increased (David and Anast, 1974).
Parathyroid secretion is normally low in the early new born period. It increases rapidly 48 h after
birth. The net effect of unknown plasma hypocalcaemic factor(s) on the one hand and parathyroid
activity on the other may account for differences in plasma Ca2+ levels observed between normal and
hypocalcaemic infants. Low levels of Mg2+ are frequently present in hypocalcaemic infants.
Hypomagnesemia may reﬂect parathyroid insufﬁciency or the converse (David and Anast, 1974)
adding uncertainty to predicting the effects of substances at this early life stage.
Taken together, the thyroid and parathyroid glands are independent organs, each having speciﬁc
functions. This, however, does not exclude the occurrence of a direct or indirect interaction in the
functions of the two systems. There is reason to believe that an insufﬁciency of the parathyroid gland
downregulates to some extent the function of the thyroid gland (Tanberg, 1916; Castro et al., 1975).
5.6.5. Summary
Infants below 16 weeks of age have speciﬁc endocrine proﬁles that are different from those in
adults. This suggests that such differences may require particular attention for the risk assessment of
substances present in food intended for infants below 16 weeks of age. Effects at any early
developmental stage may be reﬂected in deﬁcits at later time points, indicating that the window of
exposure, the window of maximum sensitivity and the window of effect require a lifespan approach to
generate a fully protective risk assessment. This is because the disruption of the programming role of
hormones during post-natal development can potentially cause adverse effects that do not become
evident until later in life. Although our scientiﬁc knowledge in this area is developing rapidly, concerted
research and development efforts are still needed to ﬁll existing knowledge gaps (Solecki et al., 2017).
6. Considerations of testing strategy for substances present in food
intended for infants below 16 weeks of age
Testing strategies for substances present in food intended for infants need to take into
consideration the differences in development stages of the relevant organ systems and the related
critical windows of maximum sensitivity between humans and laboratory animals used in safety
testing. Information on comparative differences in the post-natal development of organ systems and
physiological processes between humans and commonly used experimental animal models can be
found in the literature (WHO, 2006; Ofﬁce for Risk Assessment, 2008; Beck et al., 2016; Kuper et al.,
2016).
6.1. Information provided by standard testing of substances present in
food
The safety evaluation of substances that may be present (intentionally or not) in the foods
consumed by infants below the age of 16 weeks should follow the general principles set for the safety
evaluation processes used for substances present in food intended for the general population and
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should make use of information already obtained in standard toxicological studies following
international guidelines for toxicity testing. The testing programmes for the safety evaluation of
substances present in food used for the general population will depend on the applicable guidances12
and legislations.13 Typically, these studies will provide information on ADME, subchronic and chronic
toxicity, genotoxicity, carcinogenicity and reproductive toxicity.
6.2. Additional information needed when testing substances present in
food intended for infants below 16 weeks of age
In view of the potential greater sensitivity during the ﬁrst few weeks of life, the EFSA SC considers
that additional studies may be necessary for the risk assessment of substances intended to be
consumed by this population. These are detailed below.
When standard toxicological studies following international guidelines for toxicity testing do not
show adverse effects and the ADME studies show that a substance is not absorbed in relevant
amounts, only an additional repeated dose study with direct oral administration to neonatal animals
(e.g. in piglet models) is needed. This latter study should include analysis of possible local effects on
the gastrointestinal tract and on a possible reduction in the bioavailability of nutrients (minerals and
vitamins) that are normally contained in food for infants.
When standard toxicological studies do not show adverse effects and the ADME studies show that a
substance or its metabolite(s) is (are) absorbed, the approach as described below should be followed.
An Extended One-Generation Reproductive Toxicity Study (EOGRTS) (OECD TG 443) is warranted.
Following the EOGRTS guidelines, rats are the species of choice and the pups are (possibly) exposed in
utero, during lactation and after weaning, until at least post-natal day 42. For the purpose of this
guidance, three cohorts of F1-animals (as described in the OECD TG 443) should be included: a cohort
to assess the reproductive and developmental endpoints, a cohort to assess the potential impact of a
test substance on the developing nervous system, and a cohort to assess the potential impact on the
developing immune system. Because exposure through mother’s milk in experimental studies is usually
substantially lower than the exposure through feed, the resulting doses in the neonatal animals may
be insufﬁcient for hazard characterisation. Therefore, for the purpose of this guidance, it is advised
that direct dosing of the neonatal animals should be considered as soon as possible after birth.
In case scientiﬁc justiﬁcation is given, it is possible to deviate from the guidance given here.
For example, when a two-generation reproductive toxicity study (OECD TG 416) is available instead
of an EOGRTS, the former could be complemented with appropriate post-natal development studies
addressing (e.g. neurotoxicity and immunotoxicity). In some cases, additional studies in neonatal
animals in a second non-rodent species (e.g. the piglet models), speciﬁc in vitro assays or mechanistic
studies may be needed.
Other information
Human data (epidemiological, clinical studies and case reports, where available) should be included
in the evaluation. The general principles underpinning the risk assessment performed according to the
guidance or recommendations established by the different EFSA panels and units should be applied.
6.3. Piglet models for toxicity testing of substances present in food
intended for infants below 16 weeks of age
Piglet models, including neonatal mini piglets or neonatal farm piglets, are frequently used as an
animal model in safety and efﬁcacy research of chemicals and pharmaceuticals as they closely
resemble humans in anatomy, physiology and biochemistry and because of the practical features of
toxicity testing in piglet models (e.g. Bode et al., 2010). In particular, the gastrointestinal tract, the
12 See e.g. EFSA Panel on Food Additives and Nutrient Sources added to Food (ANS), Guidance for submission for food additive
evaluations. EFSA Journal 2012;10(7):2760. [60 pp.] https://doi.org/10.2903/j.efsa.2012.2760; EC (European Commission),
2001. Guidance of the Scientiﬁc Committee on Food (SCF) for the presentation of an application for safety assessment of a
substance to be used in food contact materials prior to its authorisation. SCF/CS/PLEN/GEN/100 Final. 19 December 2001.
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Guidance on the preparation and presentation of an
application for authorisation of a novel food in the context of Regulation (EU) 2015/2283. EFSA Journal 2016;14(11):4594, 24 pp.
https://doi.org/10.2903/j.efsa.2016.4594
13 See e.g. COMMISSION REGULATION (EU) No 283/2013 of 1 March 2013 setting out the data requirements for active
substances, in accordance with Regulation (EC) No 1107/2009 of the European Parliament and of the Council concerning the
placing of plant protection products on the market.
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cardiovascular system, the skin, the urogenital system, metabolic aspects and the immune system of
pigs are considered generally more like humans than those of other non-rodent species (Helm et al.,
2007; Guilloteau et al., 2010; Barrow, 2012; Heinritz et al., 2013; Odle et al., 2014). As in pigs no
transplacental transfer of antibodies exists, (pre)term piglets need to stay for the ﬁrst 24–48 h with
their mother for obtaining passive immunological protection by antibodies via mother’s colostral milk
(Farmer and Quesnel, 2009; Penninks et al., 2012), or by intra-arterial injection within the ﬁrst 24 h of
mother’s plasma to obtain immunological protection (Hansen et al., 2016). In addition, direct oral
administration of substances, including bottle-feeding, can be performed in this model. Therefore, the
(pre)term piglets can be considered as a relevant animal model for the safety evaluation of food
additives, pesticide residues and contaminants present in food (i.e. via pig-adapted infant formula) on
general toxicity parameters (i.e. growth, food/water consumption, haematology and clinical pathology,
toxicokinetics, organ weights and histopathology evaluations, etc.) and post-natal maturation and
development of various organ systems, such as the gastrointestinal tract (Van Ginneken, 2012; Sangild
et al., 2013), the metabolic and renal capacities (McAnulty, 2012; Preusse and Tingleff Skaanild, 2012),
the immune- and the reproductive systems (Haley, 2012; McAnulty et al., 2012), and the nervous
system (Lind et al., 2007).
As pre-term piglets delivered at 90% gestation suffer from many of the same disorders and
physiological problems as moderately immature human infants, they may comprise a relevant model
for studying the safety evaluation of early dietary interventions with food additives, pesticide residues
and contaminants present in the food of the preterm piglets and on e.g. microbiota-related
complications (Barrow, 2012).
Vaginally delivered neonatal piglets are described as a model for investigating the inﬂuences of
substances added to infant formulae on the development of the infant microbiota among other
parameters of intestinal functions (Alizadeh et al., 2015; Hoeﬂinger et al., 2015). More realistic testing
conditions are generated using interspecies transplantation of gut microbiota from the human adult
and infant gastrointestinal tract to that of piglets (Pang et al., 2007; Zhang et al., 2013; Wang and
Donovan, 2015).
6.4. Testing of the developing immune system
Despite the need for developmental immunotoxicity testing, there are no validated or widely
accepted methods for evaluating effects on the developing immune system, but there is general
consensus that when possible, methods to assess developmental immunotoxicity testing (DIT) should
be included in existing developmental and reproductive toxicology (DART) protocols (Holsapple et al.,
2005; Ladics et al., 2005; Cooper et al., 2006; Dietert and Holsapple, 2007; Burns-Naas et al., 2008;
DeWitt et al., 2012).
When testing the developing immune system, it is important to account for the fact that there are
different endpoints in the development of the immune system and in their maturation rates (US FDA,
2006). Integration of parameters reﬂecting the immune system in reproductive or developmental
guidelines is minimal to date and it is limited to the EOGRTS guideline (OECD TG 443, 2011). This
guideline is designed to provide an evaluation of the pre- and post-natal effects of chemicals on
development, as well as a thorough evaluation of systemic toxicity in pregnant and lactating females,
and also young and adult offspring, and includes additional endpoints for DIT as well as developmental
neurotoxicity. The DIT default parameters include the standard immune pathology parameters and as
this might not always be sensitive enough (Bunn and Dietert, 2001), an immune functional assay is
also included in this EOGRTS guideline. The functional assay included is a T-cell-dependent antibody
response with sheep red blood cells as an particulate antigen or keyhole limpet haemocyanin as a
protein antigen. Although not included in the EOGRTS guideline, additional functional assays might be
considered (Bunn and Dietert, 2001).
6.5. Testing of the developing nervous system
When testing the developmental nervous system to assess the safety of substances added to foods
for infants, the developmental neurotoxicity study under OECD TG 426 or as part of EOGRTS can be
used. Direct oral dosing of the pups should be considered. It was noted that the current data
requirements for developmental neurotoxicity testing may not always be sufﬁcient to identify all
potentially hazardous compounds and that additional information may be provided by appropriate
in vitro testing batteries (EFSA PRR Panel, 2013; Fritsche et al., 2017).
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6.6. In vitro assays
There is a scarcity of validated lower tier in vitro screening tests that are applicable to the ﬁrst
16 weeks of post-natal human development. There are opportunities to develop such tests that would
be relevant for example to measurement of uptake across the early gut and the brain barriers at early
life stages. Likewise, there is a need for appropriately triggered developmental neurotoxicity tests. A
recommendation follows that the existing test systems should be further developed to provide in vitro
tools that can efﬁciently pre-screen substances as part of a comprehensive risk assessment approach
for substances in food for infants below 16 weeks of age.
7. Approach for the risk assessment of substances present in food
intended for infants below 16 weeks of age
In general, it is assumed that effects observed in adults are also expected to occur in infants, which
is supported by the available evidence. The reverse may not always be the case (e.g. the developing
brain may be speciﬁcally affected or disruption of the programming role of hormones during post-natal
development may cause adverse effects that do not become evident until later in life). Most
differences between infants and adults are of a quantitative nature, i.e. the effects may occur at lower
or higher doses than in adults. Appropriate developmental studies may reveal such effects for speciﬁc
targets in that age group.
It is often assumed that the young infant is generally more sensitive than the adult. This may not
always be true, and the available evidence should be considered on a case-by-case basis.
Because considerable development is taking place in early infancy (particularly in preterm infants)
and because milk/formula consumption per kg body weight is high, and hence exposure, is greatest in
the ﬁrst month of life, the period of potentially greatest sensitivity is the ﬁrst few weeks. Moreover, this
population is heterogeneous because the post-natal age may not be representative of the actual
development of the newborn, speciﬁcally in pre-term born infants.
A decision tree to decide on the approach for the risk assessment of substances present in food
intended for infants below 16 weeks of age is presented in Figure 7. It enables a case-by-case risk
assessment taking into consideration existing data including whether relevant amounts of the
substance are absorbed and all relevant data.
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7.1. Considerations for the risk assessment of substances not
intentionally added to food intended for infants below 16 weeks of
age
The presence of contaminants in food for infants should be avoided as much as possible.
Ideally, toxicity data from neonatal animal studies should be part of the body of information needed
for the risk assessment for substances not intentionally added to food intended for infants below
16 weeks of age. However, such data might not always be available. The following section describes
how knowledge on toxicokinetic and toxicodynamic considerations can be applied to support the risk
assessment of unavoidable contaminants when data on their toxicity in infants are not available but
some data from standard toxicological studies in animals are present.
Our understanding of the maturation of the gastrointestinal tract and the brain barriers has
changed; these are now no longer considered as immature or leaky but as functional. Hence, the gut
and the brain barriers can be considered to protect the young infant at a level that may be comparable
to that seen in older infants and adults. However, it remains clear that developing organs such as the
brain and the reproductive and immune systems may be more sensitive to harm in the infant
population below 16 weeks of age as compared to the rest of the population.
The impact of the differences in toxicokinetic and toxicodynamic properties of substances in food
between infants under the age of 16 weeks and older infants or adults and potential strategies on how
to consider them in a risk assessment context are presented below.
Considerable knowledge of the ontogeny of the excretory pathways, speciﬁcally the metabolising
enzymes, permits now to predict the toxicokinetic behaviour of substances if their metabolism in the
adult is known. Even if their metabolic fate is not known in detail, the overall potential impact of the
toxicokinetic variability in infants can be addressed. To account for the variability in toxicokinetics in
the human population a kinetic subfactor of 3.2 is applied as a default value for the derivation of a
HBGV. This factor is in general appropriate. However, the differences between the adult population and
Figure 7: Decision tree approach for the risk assessment of substances present in food intended for
infants below 16 weeks of age
RP: reference point
*: This decision tree assumes that a standard chemical risk assessment has already been
performed on the substance of interest. Note that standard toxicity testing varies in the
different areas within the remit of EFSA.
**: Extended one-generation reproductive toxicity study (EOGRTS) if the substance is
systemically available, neonatal animal study if the substance is not absorbed from the
gastrointestinal tract and is not systemically available. In case scientiﬁc justiﬁcation is given,
it is possible to deviate from the guidance given here (see Section 6).
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the infants, in particular the very young ones, are in many cases greater than the factor of 3.2 and a
larger factor may be necessary (see Section 5 and Appendix C).
Most differences between infants and adults are of a quantitative nature, and therefore, lower or
higher doses of a chemical may be needed to cause adverse effects in infants as compared to adults.
However, our current knowledge of the toxicodynamic variability in infants does not allow us to predict
the magnitude of the difference in sensitivity between young infants and older infants or adults.
Furthermore, while adverse effects observed in adults are also expected to occur in infants, the lack of
observed adverse effects in adults (under standard test conditions) does not necessarily rule out a
potential speciﬁc toxicity response in young infants to the same substance. Organs with critical
developmental stages during early infancy, such as the developing brain and the immune system, may
be affected speciﬁcally. Appropriate developmental studies, as described above, may not be available.
Taking into consideration that our current understanding of the toxicodynamic variability in infants
is insufﬁcient to make general quantitative and qualitative predictions of adverse effects in infants, the
EFSA SC concludes that the uncertainty surrounding the toxicodynamic variability in infants did not
allow identifying appropriate additional toxicodynamic default UFs. However, additional considerations
on a case-by-case basis are needed to decide whether there is a health concern. In case studies on
neonatal animals are available, these are expected to address the variability discussed above.
8. Conclusions
The EFSA SC notes that during the period from birth up to 16 weeks, infants are expected to be
exclusively fed on breast milk and/or infant formula. The EFSA SC views this period as the time where
HBGVs for the general population do not apply without further considerations.
In its approach to develop this guidance, the EFSA SC has taken into account the following:
• for the exposure assessment, it is taken that in non-breastfed infants, formula is expected to
be the only source of nutrition for the ﬁrst 16 weeks of life;
• the overall toxicological proﬁle of the substance identiﬁed through the standard toxicological
tests, including critical effects;
• toxicokinetic data, especially:
 the absorption of the substance from the gastrointestinal tract impaired renal excretion metabolism in the neonatal organism compared with the adult;
• knowledge of organ development (critical windows) in human infants;
• the effects of exposure of neonatal animals at equivalent life stages of human infants;
• the relevance for the human infant of the neonatal animal models used and of the reported
effects in toxicological testing;
• whether additional relevant effects are revealed or whether the effects occurred at lower doses
in the neonatal animals, by comparison with standard toxicological studies.
The EFSA SC concludes the following:
1) High infant formula consumption per body weight is derived from 95th percentile
consumption and the ﬁrst weeks of life is the time of the highest relative consumption on a
body weight basis. Therefore, when performing an exposure assessment, the EFSA SC
proposes to use the highest consumption ﬁgures reported for the period of 14–27 days of
life (i.e. 260 mL/kg bw per day). This approach would cover acute toxicity and consider
potential periods of high sensitivity for other toxicity endpoints.
2) A decision tree approach is proposed that enables a case-by-case risk assessment of
substances present in food intended for infants below 16 weeks of age.
9. Recommendations
The EFSA SC recommends that:
1) Contemporary data on high food consumption during the ﬁrst weeks of life after birth are
generated.
2) Accurate data on exposure to substances present in food during this time period are
generated.
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3) Information from neonatal animal studies would reduce uncertainty when evaluating
substances not intentionally added to food (e.g. contaminants).
4) Guidance should be developed on how to perform studies in neonatal animals.
5) Widely acceptable models should be developed to measure antinutritional effects of
substances in food intended for infants below 16 weeks of age.
6) There is a need to develop validated in vitro tests applicable to the ﬁrst 16 weeks of post-
natal human development that could provide tools to efﬁciently prescreen substances as
part of a comprehensive risk assessment and to improve understanding of the molecular
events underlying adverse outcomes.
7) Post-marketing studies monitoring potential adverse effects (e.g. direct effects on the
gastrointestinal tract) should be made available to reduce uncertainty for substances
intentionally added to food.
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Appendix A – Overview of EU Legislation (Food Sector) covering food for
infants (and young children)
Glossary
• Infants – Children under the age of 12 months (as deﬁned in Regulation (EU) No 609/2013)
• Young children – Children aged between 1 and 3 years (as deﬁned in Regulation (EU)
No 609/2013)
FOOD ADDITIVES
Annex II to Regulation (EC) No 1333/2008 on food additives:
Speciﬁc uses of food additives in food for infants and young children (food category 13.1 of Annex II)
and speciﬁcally from birth onwards and/or for infants below 16 weeks ? additives presently authorised in food
categories ‘13.1.1 Infant formulae’ and 13.1.5.1 and 13.1.5.2 (as follows)
Infant formulae as deﬁned in Regulation (EU) No 609/2013*
Food intended for use by infants during the ﬁrst months of life and satisfying by itself the nutritional
requirements of such infants until the introduction of appropriate complementary feeding
Follow-on formulae as deﬁned in Regulation (EU) No 609/2013*
Food intended for use by infants when appropriate complementary feeding is introduced and which constitutes
the principal liquid element in a progressively diversiﬁed diet of such infants
*Commission delegated Regulation (EU) 2016/127 was adopted on 25 September 2015 and will start to apply on
22 February 2020. Until that date, the rules of Directive 2006/141/EC remain applicable
Processed cereal-based foods and baby foods for infants and young children as deﬁned in Regulation
(EU) No 609/2013**
Food intended to fulﬁl the particular requirements of infants in good health while they are being weaned and by
young children in good health as a supplement to their diet and/or for their progressive adaptation to ordinary
food
**Until the ﬁnalisation of the delegated act, the rules of Directive 2006/125/EC remain applicable
Other foods for young children
(13.1.5) Dietary foods for infants and young children for special medical purposes as deﬁned in
Regulation (EU) No 609/2013*** and special formulae for infants
***Commission delegated Regulation (EU) 2016/128 was adopted on 25 September 2015 and will start to apply
on 22 February 2019. Until that date, the rules of Directive 1999/21/EC remain applicable
(13.1.5.1) Dietary foods for infants for special medical purposes and special formulae for infants
Examples of speciﬁc uses of food additives:
From 4 months onwards in special food products with adapted composition, required for metabolic disorders and
for general tube-feeding
From 12 months onwards in specialised diets intended for young children who have cow’s milk intolerance or
inborn errors of metabolism
From birth onwards:
• in products for reduction of gastroesophageal reﬂux
• in products in liquid formulae containing hydrolysed proteins, peptides or amino acids
• for use in products based on amino acids or peptides for use with patients who have
problems with impairment of the gastrointestinal tract, protein malabsorption or inborn errors
of metabolism
• in products used in case of gastrointestinal disorders
• in products for the dietary management of metabolic disorders
• in specialised diets, particularly those devoid of proteins
Risk assessment of substances in food for infants
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(13.1.5.2) Dietary foods for babies and young children for special medical purposes as deﬁned in
Directive 1999/21/EC
Examples of speciﬁc uses of food additives:
From 4 months onwards in special food products with adapted composition, required for metabolic disorders and
for general tube-feeding
From 12 months onwards in specialized diets intended for young children who have cow’s milk intolerance or
inborn errors of metabolism
From birth onwards:
• in products for reduction of gastro-oesophageal reﬂux
• in products in liquid formulae containing hydrolyzed proteins, peptides or amino acids
• for use in products based on amino acids or peptides for use with patients who have problems with
impairment of the gastrointestinal tract, protein mal-absorption or inborn errors of metabolism
• in products used in case of gastrointestinal disorders
• in products for the dietary management of metabolic disorders
• in specialized diets, particularly those devoid of proteins
PESTICIDE RESIDUES
Regulation (EU) No 609/2013 on food intended for infants and young children, food for special medical
purposes, and total diet replacement for weight control
General requirement: Article 11(1)(b) – speciﬁc requirements on pesticides for infant formula, follow-on formula,
processed cereal-based food, baby food and food for special medical purposes developed to satisfy the
nutritional requirements of infants and young children should be updated regularly and include, inter alia,
provisions to restrict the use of pesticides as much as possible
Directive 2006/141/EC Infant formulae shall not contain residues of individual pesticides at levels exceeding
0.01 mg/kg of the product as proposed ready for consumption or as reconstituted according to the instructions
of the manufacturer. Lower MRLs apply for speciﬁc pesticides listed in Annexes VIII and IX of Directive
2006/141/EC (the same rules are laid down in Commission delegated Regulation (EU) 2016/127 that will start to
apply on 22 February 2020. Until that date, the rules of Directive 2006/141/EC remain applicable)
Follow-on formulae (same rules as for Infant formulae)
Directive 2006/125/EC Processed cereal-based foods (same rules as for Infant formulae and Follow-on
formulae) (until the ﬁnalisation of the delegated act, the rules of Directive 2006/125/EC remain applicable)
Baby foods (same rules as for Processed cereal-based foods)
Delegated Regulation (EU) 2016/128: food for special medical purposes intended for infants and young
children shall comply with the same rules laid down for formulae and baby foods (from 22 February 2019)
CONTAMINANTS
Regulation (EEC) No 315/93 laying down Union procedures for contaminants in food
Regulation (EC) No 1881/2006 setting maximum levels for certain contaminants in foodstuffs
Maximum levels for certain contaminants in foodstuffs:
• nitrate, mycotoxins, metals, polycyclic aromatic hydrocarbons and tropane alkaloids in processed cereal-
based foods and baby foods for infants and young children
• mycotoxins, metals, polycyclic aromatic hydrocarbons, melamine and inherent plant toxins in infant
formulae and follow-on formulae
• mycotoxins, metals, polycyclic aromatic hydrocarbons in foods for special medical purposes intended
speciﬁcally for infants
• metals in drinks for infants and young children labelled and sold as such, in rice destined for the
production of food for infants and young children
• dioxins and polychlorinated biphenyls in foods for infants and young children
Risk assessment of substances in food for infants
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FOOD CONTACT MATERIALS
Regulation (EU) No 1935/2004 on materials and articles intended to come into contact with food >> sets out the
general principles of safety and inertness for all Food Contact Materials (FCMs)
Regulation (EU) No 10/2011 on plastic materials and articles intended to come into contact with food
Maximum levels of speciﬁc migration limit for certain substances used in FCM for food for infants and other
restrictions:
• epoxidised soybean oil in polyvinyl chloride gaskets used to seal glass jars containing infant formulae
and follow-on formulae or processed cereal- based foods and baby foods for infants and young children
• bisphenol A not to be used for the manufacture of polycarbonate infant feeding bottles
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Appendix C – Decision tree approach to address the difference in
toxicokinetics between infants below 16 weeks of age and older
population for the risk assessment of substances not intentionally added to
food for infants below 16 weeks of age
Figure C.1: The above decision tree applies exclusively to the risk assessment of substances not
intentionally added to food for infants below 16 weeks of age. A default toxicokinetic
factor of 3.2 is typically used to account for the inter-individual human variability within
the general population. As discussed in Section 5, the differences between the adult
population and the infants, in particular the very young ones, are in many cases greater
than the default factor of 3.2 and hence necessitates an additional factor of 3 in the case
where no data are available on the excretion or metabolism of a substance not
intentionally added to food. In such case, an aggregate human UF of 30 needs to be
applied to account for the increased inter-individual toxicokinetic variability (3 9 3.2 for
TK and 3.2 for TD) that includes infants below 16 weeks of age. In case the pathway of
metabolism is known, pathway-speciﬁc or chemical-speciﬁc factors should be added to
the default factor of 3.2 to account for the increased inter-individual toxicokinetic
variability between the adult population and infants below 16 weeks of age. Case-by-case
consideration should be given whether the toxicodynamic sub-factor of 3.2 needs to be
adjusted to the situation of the physiological development of infants below the age of
16 weeks
Risk assessment of substances in food for infants
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